The Neuroprotective Effects of Pituitary Adenylate-Cyclase Activating Polypeptide (PACAP) in Focal Cerebral Ischemia by Reglődi Dóra
THE NEUROPROTECTIVE EFFECTS OF PITUITARY 
ADENYLATE-CYCLASE ACTIVATING POLYPEPTIDE (PACAP) 
IN FOCAL CEREBRAL ISCHEMIA  
 Including some additional related studies 
 
I. INTRODUCTION AND BACKGROUND 
 
I/1. CEREBRAL ISCHEMIA 
 
Cerebrovascular disease, commonly referred to as ''stroke'', is the third most common 
cause of death and leading cause of chronic disability in western countries. In 
Hungary, 40 000 patients are hospitalized with this diagnosis per year, and more than 
20 000 deaths occur due to stroke and its complications (Nagy 1999). Although a 
great deal of progress has been made in identification of risk factors, in understanding 
the pathophysiology and in diagnostic strategies, the managent of human stroke still 
remains a major clinical problem. 
 One of the main causes of stroke is the occlusion of the middle cerebral artery 
(MCA) or its branches. The therapeutic interventions that are known to be effective in 
human stroke are very limited. Dozens of new candidate therapeutic substances have 
been demonstrated to exert neuroprotection against ischemic brain damage in animal 
models of stroke. However, most of these agents are effective in animals only when 
administered either before or shortly after the onset of ischemia, which limits their 
clinical usefulness (Dyker and Lees 1998).The toxic side effects and the inability to 
cross the blood-brain barrier (BBB) are the major other reasons that most of the 
therapeutic agents proven to reduce the infarct size in experimental animals have 
failed to ameliorate human stroke outcome (Dyker and Lees 1998, Plum 1997). 
Almost all animal models of focal ischemia primarily involve unilateral MCA 
occlusion (MCAO). The two basic classes of insult are the permanent and temporary 
ischemia. There are numerous different techniques used to occlude the MCA (rev.: 
Lipton 1999). The most commonly used methods are the proximal occlusion with or 
without craniectomy. In the latter case, an intraluminal suture is inserted through the 
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carotid arteries to the origin of the MCA, before the origin of the lenticulostriate 
arteries, thereby both basal ganglia and cortical areas are damaged. The evaluation of 
the ischemic damage is most commonly done by staining brain sections with 2,3,5-
triphenyltetrazolium chloride (TTC). The staining action of TTC is based on the 
presence of intact mitochondrial enzymes, which reduce the tetrazolium salts to a 
deep red formazan compound. In necrotic tissues there is no staining, while in 
damaged, but not yet necrotic tissues the staining is pink (Bederson et al. 1986a).  
 
 
 
I/2. PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (PACAP) 
 
Pituitary adenylate cyclase activating polypeptide (PACAP) was first isolated from 
ovine hypothalami, and occurs in two amidated forms, with 38 and 27 amino acid 
residues (Miyata et al. 1989, 1990). PACAP is a member of the secretin/glucagon/VIP 
family, and has 60% sequence similarity with VIP, but its adenylate cyclase 
stimulating activity has been shown to be 1000-10,000 times greater than that of VIP. 
The primary structure of PACAP38 is identical among all mammalian species 
examined, and it also shows marked similarity with lower vertebrates and 
nonvertebrates, with differences in only 1-4 amino acids  (rev.: Arimura 1998). This 
suggests that the structure of PACAP has remained very conserved throughout 
phylogenesis and it may reflect its importance in fundamental functions in the nervous 
system.  
 Despite the high similarity between VIP and PACAP, the distribution of these 
peptides is quite different. In human tissues, PACAP38 is the predominant form, and 
PACAP27 makes up less than 10% of the total PACAP (Arimura et al. 1991). Highest 
concentration of PACAP is found in the hypothalamus, but other areas of the brain, 
including cerebral cortex, brainstem, basal ganglia, thalamus, posterior pituitary 
cranial nerve nuclei also contain PACAP immunoreactive cells (Köves et al. 1990, 
Ghatei et al. 1993, Arimura 1998). The distribution pattern of PACAP in the human 
brain is unique: it shows no similarity to the distribution pattern of other 
neuropeptides in the central nervous system (CNS) (Köves et al. 1991, Palkovits et al. 
1995). In the peripheral organs, high concentrations are found in the testis, adrenal 
medulla and pancreas, but nearly all organs contain detectable amount of PACAP 
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(Arimura et al. 1991, Köves et al. 1993). The PACAP receptor is G protein-coupled 
with seven transmembrane domains and also belongs to the VIP receptor family. At 
least eight subtypes of PAC1-receptors are found, which bind PACAP but not VIP, 
while VPAC1 and VPAC2 receptors bind both VIP and PACAP with a similar 
affinity (Arimura 1998, Harmar et al. 1998). 
 PACAP has been demonstrated to act mainly as a hypophysiotropic hormone, 
neurotransmitter and neuromodulator (rev.: Arimura 1998). The major regulatory role 
of PACAP in pituitary cells appears to be the regulation of gene expression of 
pituitary hormones and/or regulatory proteins that control growth and differentiation 
of the pituitary glandular cells. These effects appear to be exhibited directly or 
indirectly through paracrine or autocrine actions (Arimura 1998, Köves et al. 1998). 
Numerous other effects of PACAP have been reported, both in the central and 
peripheral nervous systems, as well as in endocrine and other organs. A recent review 
has summarized the current status of research on the distribution, molecular biology 
and physiological effects of PACAP (Arimura 1998).  
 
 
I/3. NEUROPROTECTIVE EFFECTS OF PACAP IN VITRO AND IN VIVO- BACKGROUND 
FOR THE PRESENT STUDY 
 
Since its discovery, increasing in vitro evidence has been accumulated on the 
neurotrophic and neuroprotective effects of PACAP in various neuronal cell cultures. 
PACAP receptor-mediated actions have been demonstrated on cell proliferation and 
survival in developing nervous systems (Waschek 1996). PACAP stimulates the 
outgrowth of neurits in different cell cultures and the survival of PC12 cells (Deutsch 
et al. 1992, Hernandez et al. 1995, Tanaka et al. 1996), and it can prevent natural cell 
death in the spinal cord of the chick embryo and in cultured cerebellar granule cells 
(Arimura et al. 1994, Canonico et al. 1996). Neurotrophic actions have also been 
demonstrated in rat cortical neurons (Morio et al. 1996b), in mesencephalic neurons 
(Takei et al.1998), in dorsal root ganglion neurons (Lioudyno et al. 1998) and in basal 
forebrain cholinergic neurons (Lindholm et al. 1999).  
 PACAP has been shown to have neuroprotective effects in various 
pathophysiological conditions (Arimura 1998, Said 1999). It protects cultured rat 
cortical neurons against glutamate-induced cytotoxicity (Morio et al. 1996a), 
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dopaminergic neurons against 6-hydroxydopamine-induced cytotoxicity (Takei et al. 
1998) and attenuates glutamate-induced neurotoxicity in hippocampal neurons 
(Changlin and Yan 1999). Dramatic neuroprotection has been observed in cultured 
hippocampal neurons at subpicomolar concentrations against a HIV envelope protein, 
gp120-induced neuronal cell death  (Arimura et al. 1994) and in a lipopolysaccharide-
induced neurotoxicity model in mixed cortical/glial cultures (Kong et al. 1999). 
Recently, it has been demonstrated that PACAP promotes the survival of basal 
forebrain cholinergic neurons in vitro and in vivo after injury (Lindholm et al. 1999, 
Skoglosa 1999). These studies indicate that PACAP is neuroprotective against various 
conditions of neurotoxicity and neuronal injury. 
A basic requirement for any in vivo neuroprotective substance is the ability to 
cross the BBB. PACAP has been proven to cross the BBB by a saturable transport 
system in mice (Banks et al.1993). The percent of the intravenously (iv) injected dose 
of PACAP38 entering the whole mouse brain is about 0.118%, which is about six 
times more than that for morphine (Banks et al. 1996). The ability to cross the BBB 
and the high influx rate have raised the possibility of PACAP being neuroprotective 
also in vivo, by systemic administration. 
The CA1 neurons of the hippocampus are highly vulnerable to transient 
forebrain ischemia and are used as a model for evaluating neuroprotective agents. 
Neuronal death in CA1 neurons is characteristically a delayed neuronal death, which 
is protracted in time during the first few days following transient ischemia, providing 
an interval for rescuing these cells. Based on the very low concentrations needed for 
neuroprotection in in vitro studies, and the efficacy of the passage of PACAP across 
the BBB, it had been postulated that very small amounts of systemically administered 
PACAP would be needed to reach the concentration necessary for its neuroprotective 
effect in the brain. It was found that PACAP38 significantly attenuated neuronal cell 
death in the CA1 area of the hippocampus by intracerebroventricular administration 
(Uchida et al. 1996), with maximum cytoprotection at 1 pmol/h over 7 days. The 
tissue concentrations of PACAP38 reached during and under this condition may 
approximate 0.1 pM which showed the greatest neuroprotection in vitro (Arimura et 
al. 1994). Significant neuroprotection was also observed by slow iv infusion of 
PACAP38 at concentrations of 16-160 pmol/h, even when treatment was delayed by 
24 hrs. The iv bolus injection prior the slow iv infusion was found to be necessary for 
the neuroprotective effect, which raises the possibility of the presence of a binding 
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protein for PACAP38 in the blood (Somogyvari-Vigh et al. 1998). Recently, the 
binding factor of PACAP38 has been identified in the human plasma as ceruloplasmin 
(Tams et al. 1999). 
   
 
I/4. EXPERIMENTAL AIMS 
 
The primary aim of the present study is to describe the neuroprotective effect of 
PACAP38 in a rat model of focal cerebral ischemia. In order to study the effects of a 
candidate neuroprotective substance, it is of extreme importance to standardize the 
method of focal ischemia, since the results obtained by different investigators show 
high variation. During the attempt to standardize the model, we have found that 
postischemic hyperthermia is an unavoidable consequence of the filament model, and 
we have conducted several experiments on the time course and the effects of 
spontaneous postischemic hyperthermia. We have studied the effects of delayed 
systemic administration of PACAP38 in a focal ischemia model, and we have 
investigated this neuroprotective effect under different experimental conditions. We 
have also studied the passage of PACAP38 across the BBB in the rat and how this 
passage is affected in focal ischema. 
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II. MATERIALS AND METHODS 
 
In the present section, materials and methods are described which have been used 
generally in our experiments. Details and modifications are mentioned in the sections 
dealing with specific experiments.  
 
 
Animals 
Adult male CD rats weighing 275-300 g were purchased from Charles River 
Laboratories and were maintained at room temperature, in an alternating 12-hr light 
and 12-hr dark cycle (lights on at 6 am). The animals were quarantined for at least 7 
days before the experiment. Before MCAO, the rats were placed in individual cages 
and fasted overnight, but allowed free access to water.  
 
Anesthesia 
The rats were anesthetized with halothane in a mixture of 70% nitrous oxide 
and 30% oxygen. Anesthesia was induced with 3% halothane and subsequently 
maintained with 1% halothane delivered with a face mask.  
 
Body temperature 
Body temperature was maintained in the normal range (36.5-37.5°C) with a 
heating lamp and a heating pad during the operation. Temperature was monitored 
with a rectal probe and kept in the normal range during the first 6 hrs after MCAO. 
According to our observations, the body temperature of most of the animals rises 15-
20 minutes after MCAO, and remains high (39-39.5°C) for a couple of hours (section 
III/4). Cooling the animals in the cold room combined with alcohol application on the 
back of the animals proved to be the only effective way to prevent temperature from 
rising above normal, which would greatly influence the size of the damaged brain 
area, and could even obliterate the effects of the tested drugs (Memezawa et al. 1995). 
Those rats which developed a too high or too low temperature, in spite of attempts to 
control the body temperature, were excluded from further experiments.   
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Focal Cerebral Ischemia 
The left middle cerebral artery (MCA) was occluded using the intraluminal 
suture technique described by Longa et al (1989). The left carotid region was exposed 
through a midline cervical incision. The common carotid artery and the external 
carotid artery below the origin of the occipital artery were ligated with a 3-0 mm 
suture. The only extracranial branch of the internal carotid artery, the pterygopalatine 
branch was also ligated to prevent incorrect insertion of the occluder filament. A 5-cm 
length of a 4-0 monofilament nylon suture (Ethilon; Ethicon Inc, France), whose tip 
had been rounded by heating near a flame and coated with poly-L-lysine (Belayev et 
al. 1996a) (Sigma) was introduced from the carotid bifurcation into the internal 
carotid artery until a mild resistance was felt (18-19 mm), thereby occluding the 
origin of the MCA. Following surgery, anesthesia was discontinued and the rats were 
allowed free access to food and water. Rats were under anesthesia for approximately 
10 minutes, including induction of anesthesia and surgical procedure. Recirculation of 
the MCA was established 2 hrs after MCAO by gentle withdrawal of the suture until 
the rounded tip reached the insertion point where a slight resistance was felt (under 
the same anesthetic conditions as surgery). 
 
Neurological Evaluation 
The neurological evaluations were carried out 2 hrs after MCAO according to 
the methods described by Bederson et al. (1986b) and Memezawa et al (1992). 
Animals with successful occlusion of the MCA showed gait disturbances with circling 
or walking to the right (corresponding to Grade 3 by Bederson et al.). Rats showing 
circling also always showed forelimb flexion, thorax twisting, decreased pain reflexes 
of the right forelimb, and decreased resistance to lateral push. Our preliminary studies 
are in agreement with those of Memezawa et al. (1992): rats which displayed these 
latter signs but without circling, did not have a satisfactory, reliable occlusion. 
Therefore, animals without circling or walking to the right were excluded from further 
experiments. Including those rats would increase the variance and could lead to 
misinterpretation of the data (section III/2). Some animals developed convulsive 
behavior, which would also influence the infarct size independently of the ischemic 
damage; therefore, those animals were also excluded (section III/2).  
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Calculation of the Infarct Volume 
All rats were decapitated under halothane anesthesia, and brains were removed 
rapidly and cooled in 98% isoamyl alcohol (Sigma) at minus 20°C for one minute. 
Two-mm-thick coronal sections were cut with the aid of a brain slicer matrix 
(Braintree Scientific Inc). Sections were immersed in 2% TTC (Sigma) for 30 
minutes, then transferred to 10% phosphate-buffered formalin for fixation. Animals 
which developed subarachnoideal hemorrhage were excluded from further evaluation. 
 Brain areas were traced and measured using an image analysis system (NIH 
Image). Unstained areas were defined as ischemic lesions (Bederson et al. 1986a). 
The areas of infarcted tissue and the areas of both hemispheres were calculated for 
each brain slice. An edema-index was calculated by dividing the total volume of the 
hemisphere ipsilateral to MCAO by the total volume of the contralateral hemisphere 
(Yanamoto et al. 1996). The actual infarct volume adjusted for edema was calculated 
by dividing the infarct volume by the edema index. The results are given as infarcted 
volume as the percentage of the total measured brain volume. 
 
Statistical Analysis 
Results are presented as the mean ± SEM. Statistical analysis was conducted 
with a one-way ANOVA followed by t-test for comparisons between groups. A t-test 
with Bonferroni correction was used for comparisons between individual histological 
sections. P < 0.05 was considered statistically significant. 
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III. STANDARDIZATION OF THE METHOD 
(Temporal evolution of the infarct size and effects of postischemic 
spontaneous hyperthermia and resurgery on the brain damage) 
 
 
III/1. BACKGROUND 
 
The most commonly used animal model of stroke is MCAO with an 
intraluminal suture. Although it was first described more than ten years ago (Longa et 
al. 1989), the optimal experimental conditions are still questions of debate (Schmid-
Elsaesser et al. 1998, Petullo et al. 1999). A recent study has pointed out that the 
numerous modifications reported in the literature indicate that the model has still not 
been standardized (Schmid-Elsaesser et al. 1998). Some authors have even admitted 
that it took months of trial and error to achieve a reproducible ischemia (Memezawa 
et al. 1992), while others have reported that it was impossible to obtain reproducible 
infarct size with the original filament model (Belayev et al. 1996a, Yanamoto et al. 
1998). 
The results obtained by different investigators have shown large variations in 
infarct sizes, which makes it difficult to compare results from different laboratories. 
The discrepancies have been attributed to a number of factors: 
 
a. Different arterial pattern and strain differences 
Anatomic variation of the MCA in the same strain and sex is one of the factors which 
is thought to be a potential source of variation in infarct size (Fox et al. 1993, Cai et 
al. 1998). This variation in the arterial pattern leads to differences in the collateral 
blood flow, which may account for the differences in infarct size. It has been shown 
that the filament model leads to larger infarct size than the craniectomy model 
because the filament model interferes with and compromises the collateral circulation, 
especially in permanent occlusion (Belayev et al. 1997, Herz et al. 1998). There is a 
considerable difference in infarct sizes between different rat strains (Markgraf et al. 
1993, Lipton 1999), which is only partly due to the arterial patterns and can also be 
attributed to difference in excitatory amino acid release (Herz et al. 1996). Substrain 
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and vendor diferences have also been demonstrated to lead to differences in infarct 
size (Oliff et al. 1995, 1996). 
 
 b. Age of animals 
Contradictory results have appeared concerning the influence of the age of animals on 
the infarct size. It has been reported that rats over 3-400 g yield to smaller and more 
inconsistent infarct sizes than younger rats (Longa et al. 1989), which may be due to a 
more developed collateral system in older rats. Others have reported the opposite: 
older rats produce significantly larger infarct volumes (Oliff et al. 1995, Sutherland et 
al. 1996)  
 
 c. Technical details 
Small changes in the technique can also greatly influence the infarct size. Using two 
different 4-0 filaments has been reported to significantly influence the infarct volume 
(Kuge et al. 1995), such as using different coatings on the filament. Suture coated 
with poly-L-lysin has been found to yield to larger infarct size and smaller individual 
variation than the uncoated sutures (Belayev et al. 1996a). Silicon coated sutures have 
also been reported to produce a reliable infarct size (Schmid-Elsaesser et al. 1998). 
 
 d. Complications of MCAO 
Hemorrhage is a complicating factor in MCAO and may occur spontaneously or 
during/after reperfusion. A recent study (Schmid-Elsaesser et al. 1998) has reported 
that subarachnoid hemorrhage is more common than previously believed. It causes 
further cerebral damage (Quereshi et al. 1999) and therefore animals with hemorrhage 
must be excluded. Convulsions are mentioned by very few reports as a complicating 
factor (Tamura et al. 1981, Uchino et al. 1994, Kim et al. 1996), which increases the 
cerebral metabolism and leads to a type of cell damage that is not related to ischemia 
(Tamura et al. 1981, Auer and Siesjo 1988). Therefore, animals with convulsive 
behavior after MCAO must also be excluded from the experimental groups. 
Premature reperfusion can also account for differences in the infarct size. A recent 
report (Schmid-Elsaesser et al. 1998) has drawn the attention to inadvertent premature 
reperfusion in the filament model which may be caused by inappropriate filament 
tightening or by movements of the animal. 
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 e. Temperature 
The protective effect of intra- and postischemic hypothermia in cerebral ischemia is 
well known (rev.: Barone et al. 1997). Hyperthermia, on the other hand, leads to 
larger infarct size. Hyperthermia is partly due to the ischemic insult itself, which 
appears to be more serious in the filament model (Zhao et al. 1994a, Lipton 1999). 
Temperature control by a heating lamp and pad during MCAO is mentioned in almost 
every paper using this technique. However, controlling the postischemic hyperthermia 
is mentioned by very few authors. Based on these observations, it is desirable to 
control the temperature when studying focal ischemia and effects of candidate 
neuroprotective drugs. Hyperthermia can not only increase the infarct size, but can 
also nullify the effects of otherwise neuroprotective drugs (Memezawa et al. 1995, 
Ginsberg and Busto 1998).  
 
 f. Anesthesia 
As mentioned previously, postoperative hyperthermia may occur with any type of 
anesthesia. The most widely used anesthesia in MCAO studies is the halothane 
anesthesia. Halothane, while anesthesia is lasting, causes hypothermia, and it has even 
been used by some investigators to reduce postoperative hyperthermia, thus 
decreasing brain damage in global ischemia (Kuroiwa et al. 1990). Halothane and 
sevoflurane have been reported to reduce the infarct size also by others (Warner et al. 
1993), but this effect seems to be merely due to hypothermia and not the direct effects 
of halothane (Kuroiwa et al. 1990). Several studies describe the beneficial effects of 
barbiturate anesthesia on the infarct size although it has not been proven in humans 
(Scheinberg 1991, Warner et al. 1991). According to these studies it is very important 
to standardize the anesthesia in order to obtain comparable experimental groups 
which are not affected by different durations of anesthesia. 
 
 g. Neurological scoring 
There are numerous different scoring systems to evaluate neurological deficits after 
MCAO. One of the most widely used is the one by Bederson et al. (1986b) who 
originally described the scoring system in rat MCAO by craniectomy. Forelimb 
flexion, decreased resistance to lateral push and circling are examined. The grading is 
0-3, with circling being the most severe (Grade 3). They have observed that when 
circling is present, the other two signs are also always present. They have found 
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correlation between the infarct size and the neurological deficit. Other studies have 
attributed only moderate deficit to circling, and designated severe deficit to those 
animals with falling or no spontaneous walking (Longa et al. 1989). Many other 
scoring systems have been described, including examination of symmetry of 
movement, reaction to touch on the trunk and vibrissae, rota-rod test, grid walking test 
and various memory tests (Yanamoto et al. 1988, Garcia et al. 1995b, Rogers et al. 
1997). Memezawa et al. (1992) have observed that only animals with walking or 
circling in one direction have successful occlusion of MCA, therefore they excluded 
all animals with no signs of circling. 
 In summary, most authors believe that examining the neurological signs is 
important, and deficits show close correlation with the infarct size. Only one study 
(Wahl et al. 1992) found no correlation between neurological deficits and infarct size, 
and they never observed circling, only exceptional rolling behavior. Filament 
insertion by any technique may not result in adequate occlusion of the MCA, 
therefore, neurological examination is important not only for grading the neurological 
deficits of the animals, but also for assessing animals with adequate, comparable 
occlusions of the MCA. 
 
 
 
III/2. TEMPORAL EVOLUTION OF THE INFARCT SIZE 
 
According to the above section, it is of extreme importance to standardize the MCAO 
model. The aim of the following experiments was to obtain the temporal evolution of 
the infarct size under our experimental conditions, and to describe the time course and 
effects of postischemic spontaneous hyperthermia, which is one of the major factors 
influencing the infarct volume. 
 
Methods 
 
MCAO was done according to the methods described in Section II. In order to obtain 
the temporal evolution of the infarct size, animals with positive neurological signs 
were sacrificed 4 (n=15), 8 (n=9), 12 (n=14), 24 (n=16), 48 (n=12) or 72 (n=10) hrs 
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after MCAO. In 15 rats no recirculation was established, these constitute the 
permanent ischemic animals, which were sacrificed 48 hrs after the occlusion. In the 
48-hr transient ischemia group, we also examined the inclusion of animals with 
questionable neurological signs, i.e.: animals which partially circle or do not circle at 
all but show other neurological signs (section III/1).  
 
 
Results and Discussion 
 
Measurements of the damaged brain areas show that infarcted brain volume was 2.2 ∀ 
0.66% 4 hrs after MCAO, 6.27 ∀ 2.1% at 8 hrs, 8.2 ∀ 2.24% at 12 hrs, 21.75 ∀ 1.5% 
at 24 hrs, 22.34 ∀ 1.18% at 48 hrs and 16.14 ∀ 3.2% at 72 hrs (Fig 1). There was no 
significant difference between the 24-, 48- and 72-hr groups. The variation was the 
smallest in the 48-hr group. Permanent ischemia resulted in an infarct size of 24.66 ∀ 
1.5%. 
  
Figure 1 
Temporal evolution of 
infarct volumes. The 
MCA was occluded for 
2 hrs, and the animals 
were sacrificed either 
4, 8, 12, 24, 48 or 72 
hrs after MCAO. 
Infarct volumes are 
expressed as the 
percentage of total 
brain volumes. 
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These results show that the infarct size gradually increased during the first 12 hrs, and 
rats seemed to respond very differently to the ischemic insult during this period, as 
indicatied by the larger standard error. The infarct size nearly reached the maximum 
at 24 hrs, while at 48 hrs, it was slightly larger, but the difference was not significant. 
After 48 hrs, the slight decrease may be due to invading normal cells that participate 
in the healing process, and stain well with TTC (Liszczak et al. 1984). Based on the 
small variation and maximum infarct size 48 hrs after the insult, we chose to sacrifice 
the animals at 48 hrs in our further experiments. 
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 If we included animals in the 48-hr transient ischemia group with no definite 
circling in the evaluation (ie.: started circling but continued to walk in a straight line) 
(n=21), the infarct volume was 17.9 ∀ 1.64%. If those animals which did not show 
circling at all (n=26), but exhibited other neurological signs were also included, the 
average infarct volume was 13.9 ∀ 1.94% (Fig 2).  
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Figure 2 
Infarct size at 48 hrs after 
MCAO in otherwise untreated 
rats. (1) animals with positive 
neurological signs, including 
circling, (2) including animals 
which circled but were also able 
to walk in a straight line, (3) 
including animals which did not 
show circling but exhibited 
other neurological signs. Infarct 
volumes are expressed as the 
percentage of total brain 
volumes. 
 
 
These results show that the selection of the animals to be included in the data 
collection must be standardized. As it has been pointed out by many investigators, 
infarct size shows high correlation with the severity of the neurological deficits 
(section III/1). In our model, if we included only those animals which clearly showed 
circling behavior and other neurological signs, and did not develop convulsions, we 
were able to obtain a highly reproducible infarct size with small variation. This is in 
accordance with the observations of Memezawa et al (1992). As we included more 
animals that showed questionable circling, the average infarct size decreased with a 
larger variation. If those animals which did not show circling with other neurological 
signs were included, the average infarct size was even smaller with an even larger 
variation (in this group, the infarct size varied from 0% to 28%). Therefore, in further 
experiments we only included animals with definite circling behavior. 
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III/3. EFFECTS OF REANESTHESIA AND LIGATION OF THE INTERNAL JUGULAR VEIN 4 
HOURS AFTER MCAO ON THE INFARCT SIZE 
 
Based on the temporal evolution of the infarct size, we planned to start administration 
of PACAP38 through a cannula in the internal jugular vein 4 hrs after MCAO. 
Therefore, it was of interest to see the effects of reanesthesia and the ligation of the 
internal jugular vein. Seven animals were reanesthetised 4 hrs after MCAO, and the 
internal jugular vein was opened and then ligated. The animals were kept under 
anesthesia for 10 minutes. In the control group (n= 12) no intervention was done after 
MCAO. 
  
 
Results and conclusions 
 
The infarct volume in the control group was 22.23 ± 1.53%, in animals where the 
internal jugular vein was ligated, it was 24.37 ± 4.3% (Fig 3). Although the average 
infarct volume resulted to be larger with a higher individual variation, the difference 
was not significant. Therefore, it can be concluded, that reanesthesia for 10 minutes 
and ligation of the internal jugular vein 4 hrs after MCAO does not significantly 
influence the infarct size.  
 
 
Figure 3 
Infarct size 48 hrs post-
MCAO in (1) control 
animals and in (2) animals 
with ligation of the internal 
jugular vein. Infarct 
volumes are expressed as 
the percentage of total 
brain volumes. 
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III/4. TIME COURSE AND EFFECTS OF SPONTANEOUS POSTISCHEMIC HYPERTHERMIA 
 
Background 
 
Body or brain temperature can substantially alter the extent of ischemic damage 
(section III/1). The neuroprotective effects of intra- and postischemic hypothermia, 
and the deleterious effects of hyperthermia, are well known (Chen et al. 1991, 
Morikawa et al. 1992, Barone et al. 1997, Maier et al. 1998). During the operation for 
MCAO, the core temperature usually falls if it is not controlled. Temperature control 
with a heating lamp or heating pad in order to avoid intraischemic hypothermia is 
mentioned by almost all researchers who use the filament technique. However, the 
control of postischemic hyperthermia is mentioned by very few authors, which could 
be due to the fact that the occurrence of postischemic spontaneous hyperthermia after 
MCAO is not a universal observation. Zhao et al. (1994a) described the time course of 
spontaneous hyperthermia and speculated that this phenomenon is a complication of 
the filament technique. Schmid-Elsaesser et al. (1998) did not observe similar 
elevations in the core temperature in a recent reevaluation of this model. 
Clinical studies have shown that stroke patients often develop mild 
hyperthermia or fever which enlarges the infarct size and worsens the outcome of 
stroke; therefore, maintaining body temperature at normothermic levels is highly 
recommended (Azzimondi et al. 1995, Reith et al. 1996, Ginsberg and Busto 1998). 
Numerous studies have demonstrated the deleterious effect of controlled hyperthermia 
for different durations in both global and focal ischemia. However, the effects of 
postischemic spontaneous hyperthermia have received little attention in animal 
research. Since stroke patients often develop hyperthermia, it is reasonable to study 
the effects of uncontrolled, fluctuating core temperatures after MCAO. 
The aim of the present study was to describe the time course of postischemic 
spontaneous hyperthermia under different experimental setups. Although 
hyperthermia has been shown to be detrimental even if it is delayed, it is well 
accepted that events during first few hours have the largest influence on brain damage 
and the potential therapeutic interventions. Therefore, we monitored the temperature 
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very closely during the first few hours, and we also examined the effects of 
spontaneous hyperthermia on the extent and temporal progression of brain damage. 
 
Methods 
 
Experiment 1 
In order to obtain the time course of changes in the core temperature after MCAO, 
temperature was measured with a rectal probe every 10 minutes during the first 2 hrs, 
every 20 minutes up until 4 hrs, and then at 5, 6, 8, 24, and 48 hrs after MCAO. 
Two groups of rats underwent 90 minutes (n=8) or 120 minutes (n=8) 
transient focal ischemia, and one group (n=8) had a permanent occlusion. These rats 
showed all the neurological signs 2 hrs after MCAO. To determine whether rats with 
an incomplete occlusion have similar rises in body temperature, 12 rats which 
exhibited no circling behavior but showed the other neurological signs after a 2-hr 
transient ischemia were used (section III/2). The sham-operated control group (n=4) 
was subjected to all of the steps for MCAO, except that the filament was introduced 
only to 10 mm, which is not sufficient to occlude the MCA.  
 
Experiment 2 
In order to examine the effect of spontaneous hyperthermia on the infarct volume, rats 
were subjected to 90 (n=10) or 120 (n=9) minutes of transient, or permanent (n=11) 
ischemia. Core temperature was strictly maintained within the normal range (36.5-
37.5°C) during the first 6 hrs after MCAO. A large area of the fur on the animal's 
back was shaved off, and when the temperature started rising above 37°C, the animals 
were placed in a cold room (4°C). In addition, alcohol (70%) application on the back 
of the animals was used in cases of a sudden rise in temperature. As soon as the 
temperature started falling below 37°C, rats were allowed to return to room 
temperature. Animals subjected to successful transient or permanent ischemia from 
Experiments 1 and 2 were decapitated under anesthesia 48 hrs after MCAO and brain 
damage was measured according to the methods described in section II. 
 
Experiment 3 
In order to examine the effect of spontaneous hyperthermia on the temporal 
progression of brain damage, rats underwent a 2-hr transient focal ischemia under the 
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same conditions as described above. Animals were sacrificed 4 hrs (n=8) or 12 hrs 
(n=8) after MCAO without any temperature control. Another group of rats was 
subjected to the same intervention, but the core temperature was strictly maintained 
within the normal range, as described in Experiment 2. Fifteen rats were killed 4 hrs, 
and 14 rats 12 hrs after MCAO. The evaluation of the extent of brain damage was 
conducted as described in section II. In this experiment, the penumbral area was also 
measured, which is indicated by the pink TTC staining (Bederson et al. 1986a). At 48 
hrs, the demarcation between infarcted and normal tissue (white and red areas, 
respectively) is quite clear, but at only 4 and 12 hrs after MCAO there is a 
considerably large area which is pink, and is localized at the margins of the white 
areas (Bederson et al. 1986a, Cole et al. 1990, Memezawa et al. 1992). The data 
obtained in this experiment were combined with the data from the animals subjected 
to a 2-hr transient ischemia in Experiments 1 and 2. 
 
 
 
Results 
 
Experiment 1 
None of the animals showed hypothermia during and after MCAO. The 
temporal profiles of the core temperatures after transient and permanent MCAO (Fig. 
4a,b,c) showed that temperature started rising 15-20 minutes after MCAO and 
reached 39-40.5°C in most animals during the first hour. There was a slight decrease 
following reperfusion at 90 or 120 minutes, but sustained hyperthermia was observed 
thereafter, during the first 8 hrs. The individual responses in body temperature showed  
variations in the time of onset of hyperthermia after MCAO and after reperfusion. In 
animals with permanent occlusion, hyperthermia was observed throughout the first 24 
hrs. The temperature decreased in all 3 groups after the first day, and the temperature 
of most animals returned to normal levels 48 hrs after MCAO.  
In animals with an incomplete occlusion (exhibited no circling behavior) of 
the MCA for 2 hrs, the pattern of changes in core temperature was similar to the 
above groups (Fig. 4d), although the rise in temperature was more delayed, and 
temperatures did not reach as high levels as in animals with complete occlusion. The 
sham-operated animals displayed only a slight increase in temperature, which did not 
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rise above 38.5°C in any animal (Fig. 4e). The onset of this slight hyperthermia was 
more gradual than in the ischemic groups.  
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Figure 4 
Core temperatures after MCAO. The data are the 
mean ± SD. (a) 90-minute transient ischemia, (b) 2-
hr transient ischemia, (c) permanent occlusion of 
the MCA, (d) animals with an incomplete, 2-hr 
transient occlusion, and (e) sham-operated control 
group. The dotted lines indicate the normal 
temperature range. Time is expressed as minutes 
and hours. 
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Experiment 2 
Temperature could be maintained within the normal range after MCAO by 
controlling it during the first 6 hrs (Fig. 5a). When cooling was discontinued, the 
animals tended to develop a slight increase in the core temperature but it did not reach 
38.5°C, and soon returned to normal levels. One of the animals displayed a core 
temperature above 39°C in spite of being placed in the cold room throughout the 
entire 6 hrs. This animal was excluded from the group. 
 
 21
 
 
34,5
35
35,5
36
36,5
37
37,5
38
38,5
39
39,5
40
40,5
41
41,5
42
0 20 40 60 80 10
0
12
0
16
0
20
0
24
0
6h 24
h
Time (minutes and hours)
Te
m
pe
ra
tu
re
 (C
)
0
5
10
15
20
25
30
35
90 minutes 120 minutes permanent
Time of reperfusion
In
fa
rc
t v
ol
um
e 
(%
)
normothermia
spontaneous hyperthermia
a 
b 
 * 
 * 
* 
Figure 5 
Spontaneous hyperthermia 
and the extent of brain 
damage. (a) Core tempera- 
tures in animals under strict 
temperature control during 
the first 6 hrs following 
MCAO. The dotted lines 
indicate the normal tempe- 
rature range. (b) Infarct 
volumes after a 90-minute 
or 2-hr transient, or after a 
permanent occlusion of the 
MCA in normothermic and 
in hyperthermic animals. 
Infarct volumes are expres- 
sed as the percentage of 
total brain volumes. *P< 
0.05 versus the normo- 
thermic groups. 
 
 
Measuring the infarct volumes after 90- or 120-minute transient, or permanent 
ischemia in rats with spontaneous hyperthermia revealed that hyperthermia 
significantly increased the brain damage in all 3 groups, when compared to the 
corresponding normothermic control groups (Fig. 5b). The infarct volumes in rats that 
underwent a 90-minute transient focal ischemia with or without temperature control 
were 10.6 ± 6.1 or 17.6 ± 6.3%, respectively. This is a 39.9% increase in the infarct 
volume, which is statistically significant (P < 0.05). A similar increase was observed 
in the groups with a 120-minute transient focal ischemia: infarct volumes were 17.9 ± 
6.5% in the normothermic and 27.4 ± 5% in the hyperthermic animals. This is a 
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34.7% increase (P < 0.05). Even animals with a permanent occlusion showed larger 
infarct volumes when temperature was not controlled: 24.7 ± 5.5% (normothermic) 
and 29.2 ± 2.9% (hyperthermic), which is a 15.5% increase (P < 0.05). A comparison 
between animals with different reperfusion times revealed that although infarct sizes 
are increased when animals display hyperthermia, reperfusion 90 minutes after 
MCAO is more beneficial than reperfusion at 120 minutes, even in animals with 
postischemic spontaneous hyperthermia (P < 0.05). However, reperfusion at 120 
minutes is adventageous when compared to permanent occlusion only when 
temperature is kept normothermic (P < 0.05); it is no longer beneficial in 
hyperthermic animals (P > 0.05). Infarct sizes in hyperthermic animals with a 90-
minute transient ischemia reached the infarct sizes of normothermic animals with a 
120-minute transient ischemia. Infarct volumes of the hyperthermic rats with a 120-
minute transient ischemia even exceeded those of the normothermic rats with 
permanent ischemia. 
 
Experiment 3 
The data of measurements of the temporal progression of the brain damage at 
4, 12 and 48 hrs are summarized in Fig. 6. When animals are sacrificed before the 
brain damage has reached its maximum, staining with TTC results in large areas of 
the brain which are stained pink at the margins of the white (infarcted) areas. These 
areas are considered to be the penumbra. There was no significant difference (P > 
0.05) between normothermic and hyperthermic animals at 4 and 12 hrs when the pink 
and white areas were added together (Fig. 6a). Total damaged brain volumes were 
10.2 ± 5.3% and 9.9 ± 4.1% in the 4-hr, and 16.9 ± 4.3% and 18.5 ± 3.5% in the 12-hr 
normothermic and hyperthermic groups, respectively. A significant difference (P < 
0.05) was observed only in the animals sacrificed 48 hrs after MCAO: total brain 
damage was 21.1 ± 6.2% in the normothermic, and 29.1 ± 5.7% in the hyperthermic 
animals, which is a 27.6% increase. However, the infarcted (white) and penumbral 
(pink) areas showed significant differences at all time points (Fig. 6b,c). The white 
areas measured 4 hrs after MCAO showed an almost three-fold (291%, P < 0.05) 
increase in the hyperthermic group compared to the normothermic control group (6.4 
± 3.1% versus 2.2 ± 2%), while the pink areas were decreased by 56.8% (P < 0.01) in 
animals with hyperthermia (3.5 ± 1.8% versus 7.9 ± 3.3%).  
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The infarcted and penumbral areas at 12 hrs showed similar differences 
between the groups, although the differences were not as marked. Infarcted (white) 
volumes were increased by 30.8% (P < 0.05) in the hyperthermic group (8.3 ± 4.1% 
versus 12.3 ± 3.2%), and penumbral (pink) volumes were decreased by 30.2% (P < 
0.05) in the hyperthermic animals (8.7 ± 2.2% versus 6.2 ± 1.9%). At 48 hrs the 
infarct volume was also significantly larger in the hyperthermic animals (17.9 ± 6.5% 
versus 27.4 ± 5%), which is a 34.64% increase (P < 0.05). The demarcation between 
infarcted and normal (stained deep red) tissues becomes quite clear 48 hrs after the 
ischemic insult; however, the pink areas still showed a significant difference between 
the normothermic and hyperthermic animals. It was 3.1 ± 1.9% in the normothermic, 
and 1.6 ± 0.6% in the hyperthermic animals, which is a 46.9% decrease (P < 0.05).  
These results clearly demonstrate that postischemic spontaneous hyperthermia 
not only increases the infarct volumes measured 48 hrs after transient and permanent 
ischemia, but also accelerates the progression of brain damage. Reperfusion shows no 
beneficial effect 2 hrs after MCAO, and penumbral areas become incorporated into 
the necrotic area at much earlier times in spontaneously hyperthermic rats than in 
normothermic rats.  
 
Discussion 
 
These results show that under certain experimental conditions, postischemic 
spontaneous hyperthermia is an inevitable complication of MCAO, and that it 
increases both the extent and the temporal progression of cerebral damage.  
 In most cases of brain injuries, brain temperatures have been shown to be 
slightly different from rectal temperatures, usually exceeding it (Jiang et al. 1991, 
Mellergard and Nordstrom 1991, Ginsberg and Busto 1998, Maier et al. 1998). 
However, rectal temperature has been proposed to reflect the changes in brain 
temperature (Zhao et al. 1994a), or even to be identical in the filament model of 
MCAO (Jiang et al. 1996), and clinical studies have mostly used core temperature 
measurements (Przelomski et al. 1986, Azzimondi et al. 1995, Reith et al. 1996); 
therefore, we found rectal measurements to be appropriate for our study. Although 
rats can change their temperature within a very short time, we found that 
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measurements made every 10 minutes closely reflected these changes and no very 
large fluctuations were ever observed. 
In the present study, we found that severe spontaneous postischemic 
hyperthermia occurs in rats following MCAO. Intraoperative warming of rats is 
mentioned by almost all investigators using the filament technique of MCAO, 
however, very few authors have mentioned the postoperative control of temperature. 
In our experiments, no hypothermia developed during the surgery, which may be due 
to the low levels and short exposure (10 minutes) to halothane. Clinical studies have 
drawn more attention to this phenomenon, since stroke patients often develop mild 
hyperthermia or fever (Przelomski et al. 1986, Azzimondi et al. 1995, Reith et al. 
1996, Ginsberg and Busto 1998). Our experimental conditions closely resembled the 
clinical conditions, because the animals were allowed to wake up and move freely 
after the 10-minute anesthesia.  
Based on the literature, the occurrence of postischemic hyperthermia is not a 
general observation in rat models of focal ischemia. In our study, we observed that 
temperatures reached very high postischemic levels. A similar degree of hyperthermia 
after MCAO in rats has been mentioned by another few investigators (Zhao et al. 
1994a, Memezawa et al. 1992, 1995). In their studies, the rise of temperature was 
observed to be much slower, i. e., the temperature reached the hyperthermic level only 
after 1-2 hours. We found that the temperature usually rose 20-30 minutes after 
MCAO, but in some individuals as soon as 15 minutes after anesthesia. This may 
reflect a difference in the MCAO technique, since according to their descriptions 
(Memezawa et al. 1992), the animals were under halothane anesthesia for much 
longer periods (20-30 minutes) than in our experiments. Spontaneous hyperthermia 
has also been observed following isoflurane anesthesia with the filament technique 
(P.-E. Chabrier, personal communication). Others have reported no spontaneous 
hyperthermia in rats (Schmid-Elsaesser 1998). The reason why postischemic 
hyperthermia is not observed by all investigators may be due to a variety of factors. It 
has been argued that hyperthermia may be strain related or be correlated with a more 
severe ischemia (Schmid-Elsaesser 1998). We observed hyperthermia in both the 90-
minute and 2-hour transient ischemia as well as in permanent ischemia. Since the 
elevations in the temperature did not significantly differ among these groups, it could 
be argued that since all rats in our experiment had elevated core temperature, the rise 
in temperature is strain related rather than dependent on the duration of the occlusion. 
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Besides strain differences, small technical details of MCAO have been reported to 
account for differences in infarct sizes (Kuge et al. 1995, Belayev et al. 1996a, Cai et 
al. 1998). Similar to the effect on the infarct size, these technical differences along 
with differences in the duration and type of anesthesia could also explain why others 
have not found postischemic hyperthermia. 
The occurrence of spontaneous hyperthermia in rat models of stroke as well as 
in stroke patients has been attributed to a variety of systemic complications and 
central factors (Przelomski et al. 1986, Wass et al. 1995, Kim et al. 1996, Loddick and 
Rothwell 1996). It has also been suggested that temperature can be an independent 
component and not an epiphenomenon of other complications in stroke patients 
(Azzimondi et al. 1995). Inflammatory factors, such as interleukin-1, have been 
suggested to play a role in the hyperthermic response following MCAO (Loddick and 
Rothwell 1996). Others have claimed (Uchino et al. 1994, Zhao et al. 1994a) that the 
rapid development of hyperthermia may not reflect an inflammatory reaction but 
rather damage to the hypothalamic temperature regulating center. Histological 
examination has revealed ischemic damage in the hypothalamus in animals subjected 
to a 2-hour transient focal ischemia and it has been argued that the intraluminal 
filament interferes with the hypothalamic circulation (Zhao et al. 1994a). Other 
studies have also showed that the intraluminal thread jeopardizes and interferes with 
the collateral blood flow (Memezawa et al. 1995, Herz et al. 1998). Coimbra et al. 
(1996) have argued that the observed hyperthermia after transient global ischemia is 
not related to the halothane treatment, that it cannot be the result of exogenous 
pyrogens, and that the temporal evolution of hyperthermia correlates well with the 
development of neuronal damage. This suggests that the severity of the ischemic 
insult may determine the release of factors inducing hyperthermia. We found that rats 
which did not have a satisfactory occlusion of the MCA also showed elevated 
temperature compared to the sham-operated animals. This also raises the possibility of 
interference with the collateral circulation, since the filament was advanced to the 
same distance as in the animals with successful MCAO, only these animals did not 
show satisfactory neurological signs. According to our observations, these animals did 
not have satisfactory occlusion of the MCA (section III/2).  
  In the present study, we found that spontaneous hyperthermia increased the 
infarct volume in both permanent and transient MCAO, regardless of the duration of 
the occlusion. Although we found that the detrimental effect of hyperthermia was not 
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as prominent in the permanent as in transient occlusion experiments, the increase in 
infarct volume was still significant. Morikawa et al. (1992) did not find significant 
effects of temperature in permanent ischemia. Memezawa et al. (1995) have also 
argued that temperature rises have a greater effect on brain lesions following transient 
than following permanent ischemia. Others (Chen et al. 1991) have observed 
increases in infarct volumes also in permanent occlusion. Kim et al. (1996) found 
exacerbation of the damage by hyperthermia after a 1-hr transient ischemia only when 
brain temperatures were kept at 40°C for 3 hrs, but not at 39°C.  
Although the brain is known to be more vulnerable to changes in temperature 
in global ischemia (Barone et al. 1997), spontaneous hyperthermia has been reported 
not to be a major aggravating factor in global ischemia by some investigators (Kato et 
al. 1991, Colbourne et al. 1993). Others have found that ischemic injury in global 
ischemia can be attenuated by preventing postischemic hyperthermia by either 
continuing anesthesia (Kuroiwa et al. 1990), or by treatment with an antipyretic drug 
(Coimbra et al. 1996). The increase in infarct volume by hyperthermia has been 
attributed to a variety of factors: neurotransmitter release, free radical formation, 
cytoskeletal degradation, interleukin-1 formation, blood-brain barrier changes, 
hyperglycemia, and various other causes (Dietrich et al. 1990, Uchino et al. 1994, 
Eilers and Bickler 1996, Kil et al. 1996, Loddick and Rothwell 1996, Morimoto et al. 
1997, Ginsberg and Busto 1998, Castillo et al. 1999). 
 The cerebral infarct has been demonstrated to progress from the lateral part of 
the caudoputamen as the ischemic core towards the cortex, which comprises the 
ischemic penumbra (Memezawa et al. 1992, Garcia et al. 1995a). TTC staining has 
been shown to be a very reliable indicator of ischemic damage after 12-24 hrs 
(Bederson et al. 1986a) when no statistical difference can be shown between damaged 
brain areas assessed by histological evaluation or TTC staining (Isayama et al. 1991, 
Memezawa et al. 1992). The border zones between normal and severely damaged 
tissues were separated by tissue which stained pink with TTC (Bederson et al. 1986a, 
Memezawa et al. 1995). Although pink staining is not an absolute indicator of 
cerebral damage, it can be an early indicator of tissue ischemia (Bederson et al. 
1986a, Cole et al. 1990). In the present study, we demonstrated that spontaneous 
hyperthermia significantly accelerates the transformation of ischemic damage from 
the less severely injured penumbral tissue to cerebral infarction. The total damaged 
brain volumes measured 4 and 12 hrs after MCAO did not show significant 
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differences; however, the distributions between penumbral and infarcted volumes 
were significantly different. This was most marked at 4 hrs, when the size of the 
infarcted tissue was increased three-fold compared to normothermic animals.  
 Hyperthermia has been suggested to increase the vulnerability of the ischemic 
region, especially the marginal zones; therefore, penumbral tissues have been 
considered to be more temperature sensitive (Chen et al. 1991, Takagi et al. 1994, 
Kim et al. 1996). Our results reinforce these observations by showing that during the 
early hours of ischemic damage, penumbral tissues become involved in infarcted 
areas more promptly if temperature is allowed to rise spontaneously. Similar effects 
have been described in global ischemia (Dietrich et al. 1990), where hyperthermia has 
been observed to play an important role in determining the temporal profile of 
ischemic damage, and hyperthermia converted ischemic cell injury to infarction more 
rapidly. We have also demonstrated that reperfusion at 2 hrs is beneficial under 
normothermic conditions, but it is no longer beneficial in hyperthermic animals. 
Hyperthermia might explain why Memezawa et al. (1992) did not find reperfusion at 
2 hrs beneficial, in contrast to others (Kaplan et al. 1991). These results are especially 
important from the clinical point of view because the penumbra during the first few 
hours is considered to be the target for therapeutic interventions (Juurlink and 
Sweeney 1997). However, spontaneous hyperthermia can attenuate or even abolish 
the effects of neuroprotective drugs (Memezawa et al. 1995), and can shorten the 
therapeutic window. 
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IV/1. NEUROPROTECTIVE EFFECTS OF PACAP38 IN FOCAL ISCHEMIA 
 
 
Methods 
 
Animal preparation, MCAO surgery, neurological evaluation and measurements of 
brain damage were carried out according to the methods described in section II. 
 
Drug administration 
The rats that showed positive neurological signs at 2 hrs after MCAO were 
randomly divided into control and PACAP-treated groups. Administration of 
PACAP38 (Polypeptide Laboratories) started 4 (n=20), 8 (n=15) or 12 (n=15) hrs 
after MCAO. The operative conditions were the same as for the MCAO surgery. A 
micro-osmotic pump with a pumping rate of 1 µl/hr (Alza Corp) was filled with 
PACAP38 dissolved in 0.1% bovine serum albumin (BSA) (Sigma). The filling and 
operational instructions given by Alza were closely followed. Pumps were prepared 
12 hrs before intravenous cannulation, and were soaked in physiological saline at 
37°C for 12 hrs. The pump was attached to micro-renathane tubing (Type MRE-040) 
(Braintree Scientific Inc). The tubing was examined after 12 hrs for the presence of 
bubbles. Those pumps that had bubbles were not used for implantation because of the 
uncertain fluid conductivity. Three cm of the tubing was inserted into the internal 
jugular vein so that the tip of the cannula was located in the right atrium. The pump 
was implanted in the subcutaneous space of the nuchal region. The infusion rate was 
160 pmol PACAP38/μl/hr, and an additional bolus injection of 5 nmol/300 μl/rat of 
PACAP38 was given intravenously (into the penal vein). These doses were chosen 
based on previous in vitro and in vivo studies (Uchida 1996). This surgical procedure 
also took approximately 10 minutes to be completed. Control groups received 0.1% 
BSA in 0.9% saline as a bolus injection and infusion 4 (n=11), 8 (n=15) or 12 (n=11) 
hrs after MCAO under the same operative conditions as the PACAP-treated animals. 
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Measurements of the physiological parameters 
In 6 randomly chosen animals in both the vehicle- and PACAP-treated groups, 
the left femoral artery was catheterized for monitoring the blood pressure, pH, arterial 
gases, blood glucose level and hemoglobin during and after surgery and after 
treatments. Blood samples were collected before, 5 min, 30 min, 2 hrs, 6 hrs and 24 
hrs after treatments. These animals were not included in further evaluations, because 
they were subjected to more extensive surgical trauma, a more prolonged anesthesia, 
and more behavioral stress than the other vehicle- or PACAP-treated animals.   
  
 
Results 
 
There was no significant difference in body weight, temperature or mortality between 
the groups. Body temperature rose in each animal 15-20 minutes after MCAO, but it 
could be maintained within the normal range by cooling the animals. Only one rat 
showed elevated body temperature in spite of cooling, this rat was excluded from 
further experiment. One or two rats died in each group, mostly during the first 24 hrs. 
Premature deaths were mainly caused by cerebral hemorrhage or extreme cerebral 
edema. Two rats in the 4- and 8-hr PACAP-treated groups, 1 rat in the 4-hr control 
group, and 3 rats in the 12-hr control group developed convulsions during the first 24 
hrs. Hemorrhage, which was not fatal, occurred in 2 rats of the 8-hr and 1 rat in the 
12-hr PACAP-treated groups, and 2 rats in the 8- and 12-hr control groups. All 
animals with convulsions or hemorrhage were excluded from further evaluation. 
There was no significant difference regarding pH (7.35 – 7.38), PCO2 (35.2 – 46.1 
mmHg), PO2 (130.0 – 149.5 mmHg), blood glucose concentration (77.0 – 95.5 mg/dl) 
and hematocrit (37.1 – 43.8%) between the control and PACAP-treated animals. The 
mean arterial pressure dropped by 30 mmHg following the PACAP bolus injection, 
but gradually returned to normal levels after 30 minutes. 
When the treatment started 4 hrs after the MCAO, the infarct volumes of the 
PACAP-treated group and the control group were 10.38 ± 2.02%  and 21.13 ± 4.02%, 
respectively (Fig. 7). This was a 50.88% reduction compared to the control group and 
was highly significant (P < 0.01). In the PACAP-treated group, the unstained areas 
are located mainly in the lateral part of the caudoputamen and the surrounding cortical 
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areas, which comprise the core of the infarct (Memezawa et al. 1992, Garcia et al. 
1995a). The anterior and medial parts of the striatum, as well as large areas in the 
cortex remained unaffected when compared to the control group. An analysis of the 
infarcted areas for each 2-mm coronal section from the control group and the group 
treated with PACAP38 starting 4 hrs after MCAO (Fig. 8a) showed that the most 
affected sections were the middle sections (3-5), which represent most of the territory 
of the MCA. The reduction of the infarct size with treatment starting 4 hrs after 
MCAO is also most pronounced in the middle sections, whereas the reduction is not 
significant in the first section. This effect can be clearly seen in the representative 
photographs of the 6 TTC-stained brain slices from the 4-hr control group and the 
PACAP-treated groups (Fig. 8b). 
 
Figure 7 
Infarct volumes after a 2-hour 
transient focal ischemia. The 
animals received either 
PACAP38 or vehicle (0.1% 
BSA in 0.9% saline) 4 hrs, 8 
hrs or 12 hrs after MCAO, and 
were sacrificed 48 hrs 
following MCAO. Infarct 
volumes are expressed as the 
percentage of total brain 
volumes. **P < 0.01 compared 
to the vehicle-treated control 
group. 
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Figure 8a 
Infarcted areas in each of the 6 
coronal sections in the 
anterior-posterior direction 
from the control and 
PACAP38-treated groups. The 
treatment was started 4 hrs 
after MCAO. *P< 0.05, **P< 
0.01. 
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When the treatment started 8 hrs after the MCAO, the infarct volumes in the 
PACAP-treated and in the control groups were as follows: control group: 19.69 ± 
2.79%, and the group treated with PACAP38 starting 8 hrs after MCAO: 15.3 ± 
2.93%  (Fig. 7). This is a substantial (22.3%), but not statistically significant (P = 
0.14), reduction in infarct volume. 
The reduction in the size of the infarct in the group treated with PACAP38 
starting 12 hrs after MCAO was also not statistically significant. The infarct size of 
the PACAP-treated group was 18.75 ± 3.31% whereas that of the control group was 
21.22 ± 1.73% (Fig. 7). This is an 11.64%  reduction in infarct size which again did 
not show significance (P > 0.05).  
 
 
Discussion 
 
These results demonstrate that systemic administration of PACAP38 effectively 
reduces infarct volume in a rat model of focal ischemia when administration begins 4 
hrs after MCAO. Infarct volumes still tend to be smaller when treatment starts 8 or 12 
hrs after MCAO, although the reductions are not statistically significant.   
Premature mortality was evenly distributed among all groups, indicating that 
the administration of PACAP38 did not contribute to the mortality. Mortalities were 
mainly due to brain edema or cerebral hemorrhage. Convulsions and subarachnoid 
hemorrhage can occur as a complication of the MCAO experiments (section III/1). 
We observed convulsions in some rats during the first 24 hrs, regardless of the 
treatment and the animals core temperature. Those animals were excluded from 
further evaluations. The occurrence of hemorrhage also showed no relation to the 
treatment.  
Among the physiological parameters, only blood pressure showed a significant 
difference between the control and the PACAP-treated animals: the intravenous bolus 
injection of 5 nmol of PACAP38 caused a prompt fall of the blood pressure, and 
returned to the preinjection level 30 minutes later. This effect of PACAP has been 
demonstrated earlier (Arimura 1998), the peptide is well known to relax vascular 
smooth muscle (Warren et al. 1992). It is possible that intravenous administration of 
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PACAP38 causes dilation of cerebral arteries and increases cerebral blood flow, 
which could be beneficial for the treatment of MCAO (Tong et al. 1993). However, 
this cannot account for the neuroprotective effect observed in this study, because 
altering the blood pressure and cerebral blood flow 4 hrs after the ischemic insult has 
no beneficial effects on infarct size (Kuroda and Siesjo 1997, Plum 1997, Dyker and 
Lees 1998). In addition, our preliminary study showed that an intravenous bolus 
injection of PACAP38 alone did not alter the infarct size after MCAO. A bolus 
injection of the peptide was given before the slow infusion because there is a PACAP 
binding protein in the circulation of rats (Somogyvári-Vigh et al. 1998, Tams et al. 
1999). It is possible that binding of PACAP38 to the binding protein would nullify the 
action of the peptide, and the bolus injection of PACAP38 was used in order to 
saturate the binding sites of the circulating binding protein.  
The present results provide an additional in vivo demonstration of the 
neuroprotective effect of PACAP38. Since its discovery, the neurotrophic and 
neuroprotective effects of PACAP have been extensively investigated in vitro (section 
I/2). These studies indicate that PACAP is neuroprotective in various 
pathophysiological conditions, at nanomolar to subpicomolar concentrations.  
PACAP has been demonstrated to readily cross the BBB (Banks et al. 1993). 
This raised the question whether a systemic administration of PACAP would be 
neuroprotective also in vivo. Indeed, its neuroprotective effect has been shown in a rat 
model of global ischemia (section I/3). In the present focal ischemia model, the same 
doses were used. Most compounds investigated as possible treatments for stroke in 
animal models are maximally effective when given as an initial bolus followed by a 
constant intravenous infusion (Plum 1997). In a recent study, it has been found that 
such an administration pattern is necessary to obtain neuroprotection with PACAP38 
(Somogyvári-Vigh et al. 1998). Our bolus injection of 15 nmol/kg bodyweight is most 
probably able to saturate the binding protein for PACAP38 in the circulation and to 
cause a rapid increase in plasma PACAP38 to the level appropriate for 
neuroprotection (Somogyvári-Vigh et al. 1998).  
The exact mechanism for the neuroprotective effect of PACAP38 remains to 
be studied. According to the studies mentioned in section I/3, it appears to be 
mediated by direct and indirect actions. The indirect effects seem to be mediated 
through astrocytes, as has been documented for VIP (Brenneman et al. 1987, 1999). 
Astrocytes have been shown to react to much lower concentrations of PACAP than 
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neurons or pituitary cells (Tatsuno et al. 1996a). It has been demonstrated that 
PACAP stimulates the proliferation of astrocytes, and the production and release of 
various neurotrophic substances, including interleukin-6 and other chemokines 
(Gottschall et al. 1994, Tatsuno et al. 1996b, Moroo et al. 1998, Brenneman et al. 
1999). In vitro, PACAP is neurotrophic at nanomolar to picomolar concentrations 
when there are no astrocytes in the culture, but at low picomolar to femtomolar 
concentrations when astrocytes are included (Arimura 1998). According to other 
observations, VIP and PACAP may exert protective effects through inhibiting 
proinflammatory factors (Martinez et al. 1998, Soares et al. 1998, Delgado et al. 
1999). PACAP has also been shown to inhibit the cyclooxigenase pathway in cerebral 
microvessels and to inhibit platelet aggregation (Kis et al. 1999a,b). PACAP has also 
been demonstrated to reduce the lipopolysaccharide-induced secretion of nitric oxide 
in mixed cortical neuron/glia cultures at very low concentrations (Kong et al. 1999). It 
is very unlikely that the concentration of PACAP38 in the brain tissue reaches the 
nanomolar range with intravenous administration of the doses we used. Therefore, it 
is likely that the neuroprotective effect of PACAP38 in vivo involves indirect 
mechanisms.  
 The data presented here suggest a promising therapeutic use for PACAP in 
cerebral ischemia. Among its practical advantages are that it readily crosses the BBB 
and is effective at extremely low concentrations. Many potential therapeutic agents 
which are effective in animal models have failed during clinical trials because of their 
toxicity (Dyker and Lees 1998). PACAP is a naturally occurring peptide, which has 
not been shown to have toxic side effects at this low dosage (Arimura 1998). More 
important, the most promising feature of PACAP is the apparently long therapeutic 
window, since it is effective even when administration is delayed for 4 hrs after 
ischemia. Several papers have described the time course of neuronal damage after an 
ischemic event (Auer and Siesjo 1988, Garcia et al. 1995a). Neuronal necrosis 
progresses from the core of the lesion towards the initially less severely damaged 
penumbral zone, which contains potentially salvageable neurons (Kuroda and Siesjo 
1997). The period available for rescuing penumbral regions is longer than for the 
ischemic focus, and rescue attempts have been directed mainly toward the penumbra 
(Juurlink and Sweeney 1997). Although there are large discrepancies between 
different studies, many authors agree that the window of opportunity for effective 
therapeutic intervention is only a few hours (Scheinberg 1991, Memezawa et al. 
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1992ab).  Most of the successful attempts to reduce infarct size have occurred when 
the treatment started either before or very shortly after the onset of ischemia 
(Scheinberg 1991). The clinical usefulness of such therapeutic agents is very limited 
due to the time interval between the recognition of the symptoms and the possible 
beginning of a treatment in stroke patients (Scheinberg 1991, Dyker and Lees 1997). 
According to recent investigations, the time window for therapeutic intervention may 
extend far beyond a few hours (Dereski et al. 1993, Marchal et al. 1996, Plum 1997, 
Shuaib and Breker-Klassen 1997) and the evolution of ischemic injury, especially in 
the penumbral regions, is more protracted in time than previously believed. A few 
studies offer some hope that even delayed treatment may have beneficial effects and 
tissue damage can be influenced long after the ischemic event (Zhao et al. 1994b, 
Zhang et al. 1996, Ginsberg and Busto 1998, Markgraf et al. 1998, Nagayama et al. 
1998, Aronowski et al. 1999, Chabrier et al. 1999). In our study, PACAP38 reduced 
infarct size when administration started 4 hrs after MCAO, and infarct volumes still 
tended to be smaller even if treatment started 8 and 12 hrs after MCAO, although this 
reduction was not significant. Changing the experimental conditions, or combining 
PACAP with other neuroprotective substances may result in PACAP being effective 
after even longer delays. 
In summary, systemic administration of PACAP38 in focal ischemia may be a 
promising therapeutic agent in stroke management. PACAP38 decreased the infarct 
volume in a MCAO model in rats even when administration began as late as 4 hrs 
after the onset of ischemia. This phenomenon needs to be investigated further in order 
to extend the window of therapeutic opportunity. 
 
 
IV/2. NEUROPROTECTIVE EFFECTS OF PACAP38 IN FOCAL ISCHEMIA UNDER 
DIFFERENT EXPERIMENTAL CONDITIONS 
 
Background 
 
Although the filament model of MCAO was described more than ten years 
ago, the optimal experimental conditions and neurological scoring systems are still 
contradictory in the literature (section III/3). Some widely accepted neuroprotective 
agents in animals have been shown to be ineffective under certain experimental 
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conditions or in different species. Hyperthermia is one such condition, which can 
greatly influence the infarct size and the effects of neuroprotective drugs (Meden et al. 
1994, Ginsberg and Busto 1998). MK-801, a glutamate receptor antagonist has failed 
to reduce the infarct size in spontaneously hyperthermic animals (Memezawa et al. 
1995). Another study has reported that MK-801 was ineffective in a thrombotic stroke 
model under conditions of either normothermic or mildly hypothermic head 
temperature (Yao et al. 1993). Oliff et al. (1996) have demonstrated that the 
protection by MK-801 was not equally effective in different rat strains and in rats 
from different vendors. Isradipine and levemopamil, Ca-channel blockers with 
promising therapeutic use in stroke (Sauter and Rudin 1990), have also failed to 
ameliorate brain damage in different animal models of both global and focal ischemia 
(Bailey et al. 1995, Gomi et al. 1995). Inconsistent results have been obtained also 
with opiate antagonists, and endothelin receptor antagonists (Obana et al. 1988, 
McAuley et al. 1996). Therefore, a very thorough investigation of the experimental 
conditions which affect the evaluation of the neuroprotective drug candidate is 
required preceding the clinical trials. We examined two common factors which might 
obscure the otherwise significant neuroprotective effect of PACAP38. In the present 
study, we report on the effects of PACAP38 on the infarct size following MCAO in 
moderately hyperthermic and normothermic rats, and on the consequences of 
including animals with questionable MCAO or convulsions. 
 
 
Methods 
 
Animal preparation, MCAO surgery, neurological evaluation and measurements of 
brain damage were carried out according to the methods described in section II.  
 
Temperature control 
The temperature of one group of rats was strictly maintained in the normal range 
(36.5-37.5oC) during the first 6 hrs (section II). In another group of rats, body 
temperature was only moderately controlled: measurements were carried out every 20 
minutes during the first 6 hrs following MCAO, and animals were placed in the cold 
room when temperature rose above 38 oC. No fur was shaved and no alcohol was 
applied. 
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Neurological evaluation 
Neurological evaluations were carried out according to the methods described in 
section II. Rats which displayed circling or partial circling but walked always to the 
right side were considered to have satisfactory occlusion of the MCA. Animals which 
partially circled but were able to walk in a straight line, or did not circle at all but 
showed other neurological signs, were considered to have an unsatisfactory occlusion 
(section III/2). Animals were observed very closely during the first 8 hrs following 
MCAO for convulsions. 
 
Drug administration 
Administration of PACAP38 started 4 hrs after MCAO, according to the methods 
described in section IV/1. From the normothermic group, animals showing all the 
neurological signs were treated with PACAP38 (n=10) or the vehicle (n=9). 
Additional rats, which showed all the neurological signs except for circling, were 
given PACAP38 (n=7) or the vehicle (n=10). From the moderately hyperthermic 
group, rats showing all the neurological signs were treated with PACAP38 (n=20) or 
the vehicle (n=10). Additional rats which showed positive neurological signs without 
circling were given PACAP38 (n=21) or the vehicle (n=11). 
 
 
Results 
 
1. Normothermic Animals 
By strictly controlling the temperature, the core temperature could be 
maintained in the normal range during the first 6 hrs following MCAO (Fig 9a). Two 
animals died in the control group, and only one animal died in the PACAP-treated 
group during the first 24 hrs. Five animals in the control, and 2 animals in the 
PACAP-treated group developed convulsion during the first 8 hrs. Four animals 
developed too high or too low body temperatures for more than 20 minutes in spite of 
strict temperature control. Including only strictly normothermic animals without 
convulsions, the infarct volumes in animals with successful occlusion of the MCA 
were 18.61 ± 3.51% in the control and 8.26 ± 2.81% in the PACAP-treated group (Fig 
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9b). This is a 55.62% reduction (P < 0.05). Including animals without definite circling 
behavior and/or convulsions resulted in infarct volumes of 17.71 ± 2.53% in the 
vehicle-treated animals and 14.53 ± 2.64% in the PACAP-treated animals (Fig 9b). 
There was no significant difference (P > 0.05) between these latter two groups.  
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Figure 9 
Normothermic animals. 
(a) Core temperatures 
after MCAO under 
strict temperature 
control during the first 
6 hrs following MCAO. 
(b) Infarct volumes 
after a 2-hr transient 
focal ischemia in 
vehicle- and PACAP-
treated animals. Infarct 
volumes are expressed 
as the percentage of the 
total brain volume. 
*P< 0.05 versus 
control group. 
 
0
5
10
15
20
25
30
Circling No definite circling and/or convulsions
In
fa
rc
t v
ol
um
e 
(%
)
control
PACAP38
b
*
2. Moderately Hyperthermic Animals 
In the animals with moderate temperature control, body temperatures rose 
above 38°C 30-40 minutes after MCAO even though the animals were placed in the 
cold room (Fig 10a). Body temperatures remained above normal in most cases during 
the 6-hr observation, although extreme rises in temperature (above 39°C) could be 
prevented. Six of the 21 control animals and 14 of the 41 PACAP38-treated animals 
died prematurely during the first 24 hrs, mainly due to extreme brain edema and/or 
hemorrhage. The difference in the mortality rates between the control and PACAP-
treated animals was not significant, but it was significantly higher than in the 
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normothermic group.  Five animals had convulsions in each group during the first 8 
hrs.  
When the animals with convulsions and/or no definite circling were excluded, 
the infarct volumes were 21.13 ± 4.2% in the control and 10.38 ± 2.02% in the 
PACAP-treated group (Fig 10b). This is a 50.88% reduction (P < 0.05). However, 
including animals with no definite circling behavior and/or convulsions resulted in 
infarct volumes of 16.71 ± 3.79% in the control animals and 14.89 ± 2.01% in the 
PACAP-treated animals, which is not a significant difference (Fig 10b).  
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Figure 10 
Moderately hyperthermic 
animals. (a) Core tempe- 
ratures under moderate 
temperature control du- 
ring the first 6 hrs 
following MCAO. (b) 
Infarct volumes after a 
2-hr transient focal 
ischemia.Infarct volumes 
are expressed as the 
percentage of the total 
brain volumes. *P<0.05 
versus the control group.  
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In summary, it is not necessary to maintain the core temperature strictly within 
the normothermic range to demonstrate a neuroprotective effect of PACAP in a rat 
model of focal ischemia. In order to demonstrate a significant neuroprotection with 
PACAP, it is necessary to exclude animals without the critical neurological sign used 
for assessing an adequate MCAO and those which develop convulsions.  
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Discussion 
 
In the present study, we showed the neuroprotective effects of PACAP38 in a 
model of transient focal ischemia produced by MCAO in normothermic and 
moderately hyperthermic rats. Infarct sizes were slightly larger in the moderately 
hyperthermic groups when compared to the normothermic animals. PACAP38 was 
almost equally effective under both conditions: it reduced infarct sizes by more than 
50%. However, if the animals without definite circling behavior and/or with 
convulsions were included in the sample, the neuroprotective effect of PACAP38 
could not be demonstrated.   
 Stroke patients often develop hyperthermia during the postinfarction period, 
which is usually slight or moderate; extreme rises in body temperature are rare, and 
are mainly associated with more severe systemic complications (section III/4) 
Experimental animals may also present with postischemic spontaneous hyperthermia, 
which can influence the size of the infarct, as also shown in this section and section 
III/4, and may modify the effectiveness of neuroprotective drugs (Memezawa et al. 
1995). According to our previous observations, sustained spontaneous hyperthermia is 
always present in rats after MCAO under our experimental conditions (section III/4). 
The animals can be maintained within normothermia by very strict temperature 
control during the first 6 hrs following MCAO. This control can be achieved by 
placing the animals in the cold room with the fur on their back shaved off and by 
applying alcohol as needed. Simply placing the animals in the cold room without 
shaving off their fur on their back and without additional alcohol application results in 
moderate hyperthermia, which rarely exceeds 38.5-39°C. Therefore, we considered 
these moderately hyperthermic animals to be appropriate to study the effectiveness of 
PACAP38 under conditions which more closely resemble the mildly hyperthermic 
condition of stroke patients. We found PACAP38 to be almost equally effective in the 
normothermic and in the moderately hyperthermic animals.  
Although MCAO with the filament technique is a widely used model of 
stroke, the optimal experimental conditions are still questions of debate (section III/1). 
Filament insertion by any technique may not result in adequate occlusion of the MCA, 
which can be responsible for large variations in infarct sizes, and may lead to 
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misinterpretation of data (Schmid-Elsaesser et al. 1998, Petullo et al. 1999). There are 
numerous neurological scoring systems to evaluate the postischemic neurological 
deficits which show a correlation with the infarct size (section III/1). Like most other 
investigators, we also examine motor deficits such as forelimb flexion, thorax 
twisting, decreased resistance to lateral push, gait disturbances with circling or 
walking in one direction, and decreased pain reflexes. We found that animals without 
circling or walking to the right did not have an adequate, reliable occlusion, while 
animals with circling always show the other neurological signs. This finding is 
consistent with the observations of Memezawa et al. (1995). Therefore, instead of 
attempts to grade the neurological signs, we considered animals with circling to have 
a satisfactory occlusion of the MCA (Memezawa et al. 1992, 1995). The absence of 
the typical neurological signs suggests that either the MCA was not adequately 
occluded, or a more highly developed collateral circulation protected the tissue 
perfused by the MCA from ischemic damage. 
A few reports have mentioned convulsions as complicating factors in MCAO 
(section III/1). We observed convulsions in a few animals in both the hyperthermic 
and the normothermic groups. It was not the aim of the present study to find a 
correlation between the occurrence of convulsions and hyperthermia or neurological 
signs. We excluded animals with convulsions from the evaluation, because seizures 
can lead to a type of cell damage that is not related to ischemia (section III/1). 
Including these animals increases the heterogenity of the brain damage in both the 
control and the PACAP-treated groups. Consequently, the difference in the infarct 
sizes between the control and PACAP-treated groups may cease to be significant. 
In conclusion, when animals were carefully selected according to the presence 
of typical neurological signs and the absence of convulsions after MCAO, PACAP38 
significantly reduced the infarct size by more than 50% in both normothermic and 
moderately hyperthermic animals, even when administration was delayed by 4 hrs 
after the insult.  
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V. PASSAGE OF PACAP38 ACROSS THE BLOOD-BRAIN BARRIER IN NORMAL AND 
ISCHEMIC BRAIN 
 
 
Background 
 
A basic requirement for any candidate neuroprotective substance for treatments of 
stroke is to cross the BBB and to reach sufficient therapeutic levels within the brain 
(He et al. 1993). The BBB is a structural and functional barrier between cerebral 
capillaries and brain parenchyma, and composed of non-fenestrated endothelial cells 
connected with tight junctions and lined with a continuos basement membrane. The 
BBB restricts free passage of large lipophobic molecules from blood to the CNS and 
vice versa. Peptides and polypeptides may cross the BBB by simple diffusion or by 
transport systems. Passage can be unilateral from blood to brain or from brain to 
blood, or bilateral. By way of these specialized transport system, the BBB regulates 
the interactions between peptides and the CNS (Banks and Kastin 1987) Therefore, 
the BBB is not a rigid, static barrier but a dynamic interface between the circulatory 
system and the CNS (Rapaport 1976, Banks and Kastin 1987, Pan and Kastin 1999b, 
Pan et al. 1999). 
The normal function of the BBB is altered by ischemia. Increased BBB 
permeability is associated with severe ischemic injury, occurring with some delay 
after the insult (Belayev et al. 1996b, Salaki et al. 1991). In general, after ishcemic 
brain injury, there are dynamic changes in the permeability of the BBB. Therefore, the 
entry of neuroprotective agents into the brain will depend on both the extent of BBB 
disruption and the substance studied. 
PACAP has been shown to cross the BBB with a saturable transport system  in 
mice (Banks et al. 1993). The percent of the intravenously injected dose of PACAP38 
entering the whole mouse brain is about 0.118% when expressed as %iv/g, which is 
about six times more than the %iv/g for morphine (Banks et al. 1996). In the present 
experiment, we examined the passage of PACAP38 across the BBB in rats, and how 
this passage is affected by focal ischemia. 
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Methods 
 
Radiolabeling of PACAP38 and Albumin 
Synthetic PACAP38 (Polypeptide Laboratories, Torrance, CA) was labeled with 125I 
(NEN Life Science Products, Boston, MA) by the lactoperoxidase method and 
purified on reversed phase HPLC on a Vydac C18 column (Rainin Instrument Co, 
Inc, Woburn, MA), with a 60-minute linear gradient of 10 to 60% acetonitrile in 0.1% 
trifluoroacetic acid.  The specific activity of the peptide was about 500 µCi/µg, as 
assayed by the self-displacement method of immunoassay (Gottschall et al. 1990) 
Human serum albumin was labeled with 99mTc using a kit (Amersham Health Care, 
San Antonio, TX). 
 
Multiple Time-Regression Analysis of Entry into the Brain 
The rate of entry into the brain of 125I-PACAP38 and 99mTc-albumin was measured. 
The right carotid artery and the penal vein of the animals were exposed.  Rats were 
given an iv injection into the penal vein of 500 µl of physiological saline containing 
0.1% BSA, 5 x 106 cpm of 125I-PACAP38, and 107 cpm of 99mTc-albumin.  
 The carotid artery was severed at 1, 2, 3, 4, and 5 minutes after the iv injection 
and whole blood was collected and centrifuged at 4˚C at 500 g for 10 minutes. 
Immediately after the collection of blood, the rats were decapitated  and the brain was 
removed. Serum and brain samples were obtained and the right and left hemispheres 
were weighed separately. The serum and the brain hemispheres were assayed for the 
radioactivity of 125I and 99mTc simultaneously. 
 To correct for the decrease of 125I-PACAP38 during iv circulation secondary 
to plasma clearance, exposure time was calculated as an integral value of serum 
radioactivity over time divided by serum radioactivity at a given time (Patlak et al. 
1983). The brain/serum ratio of radioactivity (µl/g) was plotted against exposure time.  
The slope of the linear regression line represents the influx rate, and the intercept at 
time 0 is the initial volume of distribution of 125I-PACAP38 in the brain for each 
group. 
 
Capillary Depletion Study to Determine the Compartmental  Distribution 
The anesthetized rats received an intrajugular  injection of  about 3 µCi of 125I-
PACAP38 and 4 µCi of 99mTc-albumin in 300 µl of lactated Ringer’s solution 
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containing 1% BSA, and were decapitated at 1, 3, and 9 minutes immediately after 
blood was collected from the right carotid artery.  The cerebral cortex was harvested 
and weighed (n=4 at each time point). The cortex was homogenized in a glass 
homogenizer in the capillary buffer and mixed thoroughly with 26% of dextran to 
enable effective pelleting of the capillaries of the brain (Guiterrez et al. 1993) An 
aliquot of the homogenate was centrifuged at 5,400 g for 15 minutes at 4˚C.  The 
supernatant and pellet were separated carefully and the radioactivity was measured in 
a gamma counter.  The effectiveness of the separation has been confirmed by an assay 
for the endothelial marker γ-glutamyl transpeptidase as previously reported (Guiterrez 
et al. 1993) The ratios of radioactivity of 125I-PACAP38 in the supernatant 
(parenchyma) or pellet (capillary) over serum were calculated, and the contamination 
of the vascular component was further corrected by subtraction of the 99mTc-albumin 
ratios. 
 
 
Permeability of the BBB in Different Brain Regions 
The permeability of various brain areas to 125I-PACAP38 and 99mTc-albumin was 
measured in control rats and between 4 and 48 hrs after MCAO. MCAO surgery was 
carried out according to the methods described in section II. Control rats were 
anesthetized and the carotid area was exposed but no occlusion was performed. 
 Permeability was assessed at 4, 6, 24 and 48 hrs after MCAO. Every group 
included 6-8 experimental and 2-3 control rats. The rats were anesthetized, and the 
right carotid artery was exposed. 125I-PACAP38 and 99mTc-albumin in saline/0.1% 
BSA were injected iv into the penal vein and the carotid artery was severed 3 minutes 
after the iv injection. Serum and various brain areas were collected, weighed, and the 
levels of radioactivity were measured. The tissue/serum ratios of radioactivity (µl/g) 
were calculated, and the group means were reported with their standard errors. 
  
Statistical Analysis 
 Means are reported with standard errors in repetitive measures. Statistical 
comparisons between groups were performed with one-way analysis of variance.  
Tukey’s test was used for post hoc analysis to determine which areas were 
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significantly different. Differences were considered significant when P < 0.05.  The 
GraphPad Prism program was used for the multiple-time regression analysis. 
 
 
Results 
 
Multiple Time-Regression Analysis 
The brain/serum ratios of radioactivity for 99mTc-albumin and 125I-PACAP38 were 
plotted against exposure time. For 99mTc-albumin, there was no linear regression. For 
125I-PACAP38, there was a linear regression (n=10, P < 0.05). The influx rate for 125I-
PACAP38 was 6.5 ± 2.33 µl/g min, and the initial volume of distribution in the brain 
was 102.7 µl/g (Fig 11). 
Figure 11 
Uptake rates of 125I-
PACAP38 and 99mTc-
albumin into intact rat 
brain. 125I-PACAP38 
enters the brain rapidly 
after an iv injection with 
an influx rate of 6.5 µl/g-
min. In contrast, there was 
no significant entry of 
albumin (0.02 µl/g/-min).
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Capillary Depletion Study 
At 1, 3, and 9 minutes after iv injection in the rats, there was a significantly greater 
amount of 125I-PACAP38 in the brain parenchyma compared with the capillaries (Fig. 
12) (1 min: F(1,6) = 8.80, P < 0.05; 3 min: F(1,6) = 26.48, P < 0.005; 9 min: F(1,6) = 
25,25, P < 0.005). 
 Figure 12 
Brain parenchyma or brain 
capillary/serum ratios vs. 
exposure time for 125I-
PACAP38 after correction 
for contamination of the 
vascular component by 
subtraction of the 99mTc-
albumin ratios. Each point 
represents the mean ±SEM 
(n = 4/group.) * P < 0.005 
compared the parenchyma 
to the vasculature. 
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Permeability of the BBB after MCAO 
The effects of left MCAO on the entry of 99mTc-albumin into both hemispheres are 
shown on Figure 13. On the side with transient occlusion, there was a significant 
decrease at 4 hrs (P < 0.01).  In the contralateral  hemisphere, the decrease in the entry 
of albumin was significant at 4, 6, and 24 hrs (P < 0.05). Comparisons between the 
left and right hemispheres, however, were not significant. 
Figure 13  
Uptake of 99mTc-albumin 
into the intact (right) and 
damaged (left) hemisphere 
after 2 hrs of transient 
MCAO at different time 
points. Each point 
represents the mean ±SEM 
*P < 0.05, ** P < 0.01 
compared to the 
ipsilateral hemisphere of 
the control group. 
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 The entry of PACAP38 was 7–14 times  greater  than that of albumin at each 
time and also showed a transient decrease after MCAO, with a maximal decrease of 
36% on the damaged hemisphere.  The nadir was reached at 6 or 24 hrs after 
occlusion, later than that seen for albumin. We calculated the differential 
permeability, expressed as the ratios of 125I-PACAP38 over 99mTc-albumin. As seen in 
Figure 14, there was a trend for an increase soon after reperfusion followed by a 
significant decrease at 24 hrs after MCAO (P < 0.05 for the right hemisphere, and P < 
0.01 for the left). There was no significant difference between the two hemispheres at 
any time, and each showed about a 20% increase at 4 hrs and a 45% decrease at 24 
hrs. At 48 hrs the differential permeability returned to the baseline. 
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Figure 14 
Uptake of 125I-PACAP38/ 
99mTc-albumin into the right 
(intact) and left (damaged) 
hemisphere after 2 hours of 
transient MCAO at different 
time points. Each point 
represents the mean ±SEM 
(n = 6-8/group.) * P < 0.05, 
** P < 0.01 compared to 
the ipsilateral hemisphere 
of the control group. 
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 To distinguish the selective susceptibility of the cortex, striatum, and the rest 
of the hemisphere, the differential permeability in each of the divided regions was 
plotted in Figure 15.  In general, the temporal changes in all regions followed a 
similar pattern. 
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Figure 15 
Distribution of 125I-PACAP38/ 
99mTc-albumin uptake between 
the intact (right) and damaged 
(left) part of the cortex (a), 
striatum (b) and the remaining 
portion of the hemisphere (c) 
after 2 hours of transient 
MCAO at different time points. 
Each point represents the 
mean ±SEM  * P < 0.05, ** P 
< 0.01 compared to the 
ipsilateral hemisphere of the 
control group. 
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Discussion 
 
In the normal rat, PACAP38 entered the rat brain rapidly after a bolus injection, 
shown by an influx rate of 6.5 µl/g-min. This is even higher than that seen in mice (Ki 
of 2.86 ± 0.57 µl/g-min) where a saturable transport system across the BBB has been 
shown (Banks et al. 1993).  In comparison, epidermal growth factor, which also has a 
rapid and saturable entry, has an Ki of about 2.0 µl/g/min (Pan and Kastin 1999a, Pan 
et al. 1999), whereas most neurotrophins have influx rates ranging from 0.2 to 0.8 
µl/g-min (Pan and Kastin 1999b). By contrast, 99mTc-albumin included in the same 
injection did not significantly penetrate the BBB, indicating that the albumin detected 
in the brain is confined to the cerebral vasculature, and that PACAP38 did not alter 
the vascular space. 
 In addition to the high influx rate, PACAP38 also had a high initial volume of 
distribution in the brain (102.7 µl/g).  This may indicate that PACAP interacted with 
the cerebral vasculature or had a significant entry during the first several minutes, as 
seen with brain-derived neurotrophic factor (Pan et al. 1998). We, therefore, 
compared the compartmental distribution of PACAP38 shortly after an iv injection by 
separating the accumulation of PACAP38 in brain parenchyma vs. vasculature.  
Figure 12 shows that PACAP38 in brain parenchyma was significantly higher even at 
1 minute (P < 0.05) after an iv injection.  In addition, a previous study using HPLC 
proved that most of the PACAP38 entering brain was intact at 5 minutes (Banks et al. 
1993). Therefore, PACAP38 is a promising candidate for providing neurotrophic 
support to the CNS after systemic delivery. 
Left MCAO followed by reperfusion 2 hrs later caused a dynamic change in 
the entry of albumin from blood to brain, reflected by the ratios of radioactive 
albumin in brain over blood [(cpm/g)/(cpm/µl)]. There was a transient decrease in the 
accumulation of albumin at 4 hrs on both sides of the brain, the ipsilateral side 
showing a more prominent decrease. However, the decrease of albumin entry into the 
contralateral hemisphere seemed to be more long-lasting, and did not return to 
baseline until 48 hrs later. We speculate that these changes are initially related to the 
cessation of blood flow to the distribution of the left MCA, followed by global 
changes that lead to hypoperfusion of the whole brain, such as systemic hypotension, 
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release of vasoactive substances, or redistribution of blood flow (Nagasawa and 
Kogure 1989, Slater et al. 1977). We did not observe disruption of the BBB during the 
study, as assessed by any of the ratios of albumin entry after an iv injection. This is 
consistent with the study by Gotoh et al. (1985), showing that an increase in the 
permeability to albumin is not significant until 3 days after the ischemic event.  Our 
results are different from those of Hatashita and Hoff (1990), who found that the 
albumin transfer index increased at 12 hrs and peaked at 72 hrs. Discrepancies 
between this report and our observation are probably related to differences in the 
animal models. In their experiments, occlusion was introduced by the transretroorbital 
approach, without reperfusion. The slight reduction rather than increase in BBB 
permeability to albumin most likely resulted from reduced capillary perfusion (Betz et 
al. 1994).  
 The alterations of PACAP38 entry into brain after MCAO and reperfusion 
followed a different temporal course than that of albumin. The maximal decrease of 
PACAP38 entry occurred between 6–24 hrs after MCAO, much later than that seen 
for albumin.  This could not be explained by the delay in reperfusion, because once 
the cerebral blood flow in the ischemic areas was restored, PACAP38, about two-
thirds the size of albumin, should have more readily penetrated the partially disrupted 
BBB. 
 We next calculated the differential permeability, expressed as the ratio of 
PACAP38 entry vs. albumin entry.  The values initially increased at 4 hrs, followed 
by a significant decrease at 24 hrs. If there were two inert substances crossing the 
BBB by simple diffusion, the differential permeability would have remained the same 
when the barrier was completely disrupted, and increased when there was increasing 
restriction in diffusion secondary to the restoration of the barrier function, so that the 
smaller substance passed the barrier more easily. Therefore, the differential 
permeability could serve as a sensitive marker for partial disruption of the BBB 
(Ziylan et al. 1984). Early and partial disruption of the BBB has been shown by a 
fluorescent quantitative method (Belayev et al. 1996b). However, the time course of 
fluctuation of differential permeability in our study does not correlate well with the 
Evans Blue fluorescence. Most likely, the changes of differential permeability of 
PACAP/albumin is attributable to the dynamic changes of the transport system of 
PACAP38 across the BBB. 
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 We noticed that the decrease in the entry of albumin and PACAP was present 
in both hemispheres, and the differential permeability in different structures in the 
ischemic core and penumbral region was similar. It is possible that MCAO triggered 
secondary events, such as the release of vasoactive substances, that changed cerebral 
perfusion and the permeability of the BBB in general. Again, the changes of 
PACAP38 entry suggested specific interactions of this bioactive peptide with the 
BBB. It was previously reported that lesions impairing the BBB do not entirely 
abolish the saturable transport system for substances that are actively involved in the 
pathological processes (Banks et al. 1998, Pan and Kastin 1999b). After spinal cord 
injury by transection (Pan et al. 1997) or by compression (Pan et al. 1999), the 
permeability of the BBB is increased distal to the lesion, whereas the transport system 
for tumor necrosis factor α (TNF) is upregulated. Similarly, experimental 
autoimmune encephalomyelitis causes transient breakdown of the BBB as well as 
enhances the blood-to-CNS entry of TNF (Pan et al. 1996). For PACAP38, there 
seems to be a down-regulation of the transport system. After spinal cord injury by 
transection in the lumbar region in the mouse, there is a prolonged depression of the 
influx of PACAP38 into the brain and spinal cord cephalic to the lesion, followed by 
an increase 1 week later. These changes are related to alterations of the saturable 
transport system and inhibitable by excess unlabeled PACAP38 (Banks et al. 1998). 
In the current study, we showed that the entry of PACAP38 decreased after 
reperfusion following MCAO. The decrease was not explained  by general alterations 
of cerebral blood flow or disruption of the BBB. Thus, this study provides another 
example that the BBB is actively involved in the pathophysiology of CNS disorders 
and regulates the availability of bioactive substances from blood. 
 In summary, PACAP38 had a rapid influx after an iv injection in the rat and 
was available to the brain parenchyma. Unilateral MCAO was associated with an 
altered function of the PACAP38 transport system of the BBB, leading to a transient, 
global decrease in the influx of PACAP38. 
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VI. APPENDIX 
PRELIMINARY STUDIES FOR FURTHER INVESTIGATION OF THE NEUROPROTECTIVE 
EFFECTS OF PACAP IN OTHER MODELS OF NERVOUS INJURY  
- PACAP IN THE EARTHWORM 
 
Introduction and background 
 
The annelid nervous system is a favorite model in invertebrate neuroscience. It has 
long been known that if pieces of the nerve cord or the cerebral ganglion of the 
earthworm are removed, morphological as well as functional regeneration takes place 
(Aros and Vigh 1962, Koritsanszky and Hartwig 1974, Cornec et al. 1987). This 
unique capacity of the earthworm nervous system to regenerate provides an excellent 
model for studying mechanisms of, and substances involved in neural regeneration. 
(Yogev et al. 1991, Lyckman and Bittner 1992, Todorov et al. 1992, Krause et al. 
1994, Lore et al. 1999). 
It has recently been demonstrated that PACAP may be involved in axonal 
regeneration following peripheral nerve injury and traumatic brain injury (Zhang et al. 
1996, Lioudyno et al. 1998, Skoglosa et al. 1999). In order to examine the possible 
role of PACAP in an invertebrate model of nervous regeneration, the first step was to 
demonstrate the occurrence of PACAP in tissues of the earthworm. Based on the 
extremely conserved structure of PACAP throughout phylogenesis (section I/2), and 
the numerous vertebrate-like peptides demonstrated in annelids (Dhainaut-Courtois et 
al. 1985, Curry et al.1989, Al-Yousuf 1990, Satake et al. 1999), we assumed that 
PACAP might also occur in oligochaete worms. It has been found that PACAP shows 
marked similarity to human PACAP27 even in a nonvertebrate, protochordate species 
(McRory and Sherwood 1997). Besides these results, only scarce studies have been 
published on the function of PACAP-like substances in invertebrates (Zhong 1995, 
Zhong and Pena 1995), and little is known about the occurrence of this peptide in 
lower animals. First we mapped the distribution of PACAP38-like immunoreactivity 
using immunohistochemistry, which was followed by radioimmunoassay (RIA), 
HPLC and bioassay studies. In the present section, these recent findings are 
summarized without the intention of detailed description. 
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Methods  
 
For immunohistochemical purposes, adult specimens of 3 earthworm species, Eisenia 
fetida, Lumbricus terrestris and Lumbricus polyphemus were used. Serial cryostate 
sections were stained according to the peroxidase-antiperoxidase method, using 
PACAP38 antiserum (Peninsula), which was followed by silver intensification in 
some of the sections. 
 For RIA purposes, cerebral ganglia, subesophageal and ventral nerve ganglia 
were collected from 30 animals (Lumbricus polyphemus). Different parts of the 
alimentary tract (foregut, stomach, midgut and hindgut) were removed from 5 
animals, gonads and metanephric tubules from 10 worms.  Tissues were processed for 
RIA and assayed for PACAP27 and 38 using a highly specific RIA procedure 
(Arimura et al. 1991). PACAP27 antibody was generated against synthetic PACAP27 
and recognizes PACAP27 but not PACAP38. The PACAP38 antiserum was 
generated against synthetic PACAP(24-38) and recognizes PACAP38 as well as 
peptides containing the epitope of PACAP(24-38), but not PACAP27. The lyophilised 
extracts from the cerebral ganglia and ventral cord were purified, concentrated and 
then subjected to reverse-phase high performance liquid chromatography (RP-HPLC). 
 The biological activity of the HPLC fractions were determined by their ability 
to accumulate extracellular cAMP in pituitary cell cultures (Tatsuno et al. 1991). 
Pituitary cells from adult female CD rats were cultured for 3 days, then the dried 
HPLC fractions dissolved in the media were added to the cells. After 3 days 
incubation, cAMP was determined by RIA (Gottschall et al. 1988). 
 
 
Results  
 
As demonstrated by immunohistochemistry, the distribution pattern of PACAP38-like 
immunoreactivity was similar in all 3 species studied. The cerebral ganglion contains 
numerous immunoreactive cells in the dorsal cell mantle, and fibers are intensively 
stained in the central neuropil. The subesophageal and ventral cord ganglia also 
displayed immunoreactive cells and fibers, although the number of cells was much 
less. In the peripheral nervous system, immunoreactivity was found in the enteric 
nervous system, in epidermal sensory cells and in the clitellum (Figs 16, 17).  
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Figure 16 
Distribution of PACAP38-like immunoreactivity in the CNS of annelids. (a) Dorsal 
immunoreactive cells in the cerebral ganglion of Lumbricus polyphemus (arrows). (b) 
Cerebral ganglion of Eisenia fetida: immunoreactive cells along the dorsal cellular 
mantle (arrows), immunoreactive fibers in the central neuropil (star) at the 
originating part of the connective (arrowhead). (c) Centromedial cells in the caudal 
part of the cerebral ganglion in Lumbricus polyphemus (arrows). (d) Ventromedial 
immunoreactive cells in the subesophageal ganglion of Eisenia fetida (arrows). (e) 
ventromedial immunoreactive cells in the ventral cord ganglion of Lumbricus 
terrestris (arrows). (f) Immunoreactive fiber network in the central neuropil of the 
ventral cord ganglion of Lumbricus terrestris (star). Bars represent 50 micrometers 
in a,b,d,e,f, and 75 micrometers in c.  
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Figure 17 
PACAP38-like immunoreactivity in the enteric system, epidermis and clitellum of 
annelids. (a) Stomatogastric ganglionic cells in Lumbricus polyphemus (arrows). (b) 
Immunoreactive fibers in the pharynx of Eisenia fetida (arrowheads). (c) An 
immunopositive epithelial cell in the pharyngeal wall of Lumbricus polyphemus 
(arrow). (d) Epidermal sensory cells in Lumbricus terrestris (arrows). (e) Ventral 
ganglion in the clitellum of Lumbricus terrestris: ventromedial (arrow) and lateral 
(arrowheads) cells and an intensely stained central neuropil (stars). (f) Subepithelial 
cells in the clitellar part of the intestines of Lumbricus terrestris (arrows). Bars 
represent 50 micrometers on a-e and 100 micrometers on f.  
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 As measured by RIA, the amount of endogenous PACAP showed a marked 
topographical variation in the tissues of the earthworm (Table 1). Cerebral ganglion 
and ventral cord contained the highest concentration of PACAP. The concentration of 
PACAP27 was 10-15 times higher than that of PACAP38. The subesophageal 
ganglion had significantly less PACAP27 and 38 compared to other parts of the CNS. 
The foregut also contained a substantial amount of PACAP27 and 38, and the 
PACAP27 content was about 3 times higher than PACAP38. The gizzard, midgut and 
hindgut had about the same level of both PACAP residues and the concentration was 
significantly less than in the foregut. The nephridial system also contained a 
significant amount of PACAP27 and 38 comparable to the foregut. The concentration 
of the two residues was about the same in this system. In the reproductive system, the 
PACAP38 content was 10 times higher than the PACAP27. The serial dilutions of the 
various extracts yielded a displacement curve parallel to that of synthetic PACA38 
(Fig 18) and PACAP27 in respective RIA (Fig 19). 
 
Table 1.  Tissue content of immunoreactive 
PACAP 27 and 38  
 
Tissues PACAP27 PACAP38 
 
Cerebral ganglia 14.42 ± 1.22 1.51 ± 0.24 
Subosephageal ganglia 0.73 ± 0.43 0.13 ± 0.02 
Ventral cord 17.12 ± 2.52 0.95 ± 0.21 
Foregut 2.14 ± 1.21 0.72 ± 0.06 
Gizzard 0.03 ± 0.01 0.06 ± 0.01 
Midgut 0.19 ± 0.04 0.01 ± 0.01 
Hindgut 0.31 ± 0.06 0.32 ± 0.04 
Excretory system 1.17 ± 0.32 0.82 ± 0.22 
Seminal vesicle 0.18 ± 0.04 0.32 ± 0.03 
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RP-HPLC analysis was employed to characterize the PACAP 
immunoreactivity in the earthworm nervous system. HPLC fractions were assayed by 
RIA for PACAP27 and PACAP38 using PACAP antisera with different recognition 
site. PACAP27 immunoreactivity was assayed by the PACAP27 antiserum (88123-3), 
which recognize PACAP27 but not PACAP38. The extract peaked in fraction 22 
which corresponds to synthetic PACAP27 (Fig 20a). Using the PACAP38 antiserum 
(88111-3) which could detect PACAP38 and peptides containing a sequence of 
Figure 19 
D se r sponse curves 
for PACAP27 standard 
and for Lumbricus 
polyphemus tissue 
extracts. The dilution 
curves of various tissue 
extracts are parallel 
with synthetic 
PACAP27. 
0
2 0 0 0
1 1 1 2 1 3 1 4 1
F ra c ti o n s
4 0 0 0
6 0 0 0
8 0 0 0 P A C A P 2 7
1 0
6 0
A c e to n itr ile  %
Figure 20 
RP-HPLC elution 
profile of PACAP-li in 
Lumbricus poly- 
phemus tissue ex-
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PACAP24-38, but not 27, showed a single peak in fraction 19 co-eluted with 
synthetic PACAP38 (Fig 20b). 
 
 The fractions of the cerebral ganglia and ventral cord showed two distinct 
bioactive peaks (Fig 21), which were co-eluted with PACAP38 and PACAP27 
respectively. This indicates that the PACAPs extracted from the earthworm have 
adenylate cyclase activating activity. 
 
 
 
 
 
 
Summary 
 
Our present results provide evidence that PACAP-like peptides occur  in oligochaete 
worms. This is the first detailed description of PACAP-like immunoreactivity in an 
invertebrate species. Serial dilutions of the extracted tissues showed a high degree of 
structural homology to PACAP27 and 38 standards suggesting a similar amino acid 
sequence to human PACAPs. The extract of these tissues showed a distinct bioactivity 
as measured by cAMP accumulation from cultured rat anterior pituitary cells. Based 
on the distribution pattern it can be suggested that these peptides play a role in 
nervous transmission and/or modulation, and in other functions of the gastrointestinal, 
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reproductory and excretory systems. Our results provide the basis for future studies on 
the role of PACAP in neuroregeneration of the earthworm.  
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VII. SUMMARY OF NEW FINDINGS 
 
1. We have shown that postischemic spontaneous hyperthermia is an inevitable 
consequence of middle cerebral artery occlusion in rats under certain experimental 
conditions. This spontaneous hyperthermia not only increases the infarct size, but 
accelerates the incorporation of penumbral tissues into the necrotic area. This is most 
pronounced during the first 4 hours, which is the main target period for therapeutic 
interventions. Also, reperfusion after 2 hours is no longer beneficial in hyperthermic 
animals. 
 
2. We have demonstrated the neuroprotective effects of PACAP in focal ischemia. It 
was found that PACAP reduced the infarct size by more than 50%, even when given 4 
hours after the onset of ischemia. This effect is not influenced by moderate 
hyperthermia.  
 
3. We have demonstrated that PACAP crosses the blood-brain barrier in rats. This 
passage is altered after middle cerebral artery occlusion: all regions of the brain show 
a selective increase in the passage of PACAP38 across the blood-brain barrier 4 hours 
after the occlusion, which is not related to generalized changes in the permeability. A 
significant decrease in the passage is observed 6 and 24 hours after MCAO, but it 
returns to baseline levels 48 hours after occlusion.  
 
4. We have shown that PACAP occurs in Oligochaeta by immunohistochemistry and 
RIA. PACAP27 seems to be the major form in the nervous tissue, and PACAP38 in 
the reproductive system, although all tissues contain detectable levels of both forms. 
The HPLC extracts from tissues show biological activity.  
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IX. Abbreviations 
 
 
BBB   Blood-brain barrier 
BSA   Bovine serum albumin 
CNS   Central nervous system 
MCA   Middle cerebral artery 
MCAO  Middle cerebral artery occlusion 
TTC   Triphenyl tetrazolium chloride 
iv   intravenous 
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